BMND8
MCID: BNM022
MIFTS: 40

Bone Mineral Density Quantitative Trait Locus 8 (BMND8)

Categories: Bone diseases, Fetal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Bone Mineral Density Quantitative Trait Locus 8

MalaCards integrated aliases for Bone Mineral Density Quantitative Trait Locus 8:

Name: Bone Mineral Density Quantitative Trait Locus 8 58
Osteoporosis 58 74
Osteoporosis, Susceptibility to 58
Bmnd8 58

Classifications:



External Ids:

OMIM 58 611739
UMLS 74 C0029456

Summaries for Bone Mineral Density Quantitative Trait Locus 8

MalaCards based summary : Bone Mineral Density Quantitative Trait Locus 8, also known as osteoporosis, is related to osteoporosis and osteoporosis, juvenile, and has symptoms including tremor, angina pectoris and back pain. An important gene associated with Bone Mineral Density Quantitative Trait Locus 8 is BMND8 (Bone Mineral Density Quantiative Trait Locus 8). The drugs Selenium and Protective Agents have been mentioned in the context of this disorder. Affiliated tissues include bone, liver and kidney.

Description from OMIM: 611739

Related Diseases for Bone Mineral Density Quantitative Trait Locus 8

Diseases in the Bone Mineral Density Quantitative Trait Locus 18 family:

Bone Mineral Density Quantitative Trait Locus 4 Bone Mineral Density Quantitative Trait Locus 1
Bone Mineral Density Quantitative Trait Locus 2 Bone Mineral Density Quantitative Trait Locus 3
Bone Mineral Density Quantitative Trait Locus 5 Bone Mineral Density Quantitative Trait Locus 6
Bone Mineral Density Quantitative Trait Locus 7 Bone Mineral Density Quantitative Trait Locus 8
Bone Mineral Density Quantitative Trait Locus 9 Bone Mineral Density Quantitative Trait Locus 10
Bone Mineral Density Quantitative Trait Locus 11 Bone Mineral Density Quantitative Trait Locus 12
Bone Mineral Density Quantitative Trait Locus 13 Bone Mineral Density Quantitative Trait Locus 14
Bone Mineral Density Quantitative Trait Locus 15 Bone Mineral Density Quantitative Trait Locus 16
Bone Mineral Density Quantitative Trait Locus 17

Diseases related to Bone Mineral Density Quantitative Trait Locus 8 via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 611, show less)
# Related Disease Score Top Affiliating Genes
1 osteoporosis 13.0
2 osteoporosis, juvenile 12.8
3 osteoporosis-pseudoglioma syndrome 12.7
4 nephrolithiasis/osteoporosis, hypophosphatemic, 1 12.5
5 glucocorticoid-induced osteoporosis 12.5
6 juvenile primary osteoporosis 12.5
7 nephrolithiasis/osteoporosis, hypophosphatemic, 2 12.4
8 osteoporosis and oculocutaneous hypopigmentation syndrome 12.3
9 growth failure, microcephaly, mental retardation, cataracts, large joint contractures, osteoporosis, cortical dysplasia, and cerebellar atrophy 12.1
10 amino aciduria with mental deficiency, dwarfism, muscular dystrophy, osteoporosis, and acidosis 12.0
11 macroepiphyseal dysplasia with osteoporosis, wrinkled skin, and aged appearance 12.0
12 hajdu-cheney syndrome 12.0
13 cutis laxa osteoporosis 12.0
14 dominant hypophosphatemia with nephrolithiasis or osteoporosis 12.0
15 osteoporosis-macrocephaly-blindness-joint hyperlaxity syndrome 12.0
16 lrp5-related primary osteoporosis 12.0
17 bone mineral density quantitative trait locus 18 11.9
18 bone mineral density quantitative trait locus 15 11.9
19 acroosteolysis dominant type 11.8
20 bone mineral density quantitative trait locus 16 11.7
21 premature ovarian failure 1 11.5
22 bone mineral density quantitative trait locus 12 11.5
23 werner syndrome 11.3
24 lysinuric protein intolerance 11.3
25 rickets 11.3
26 mental retardation, x-linked, syndromic, snyder-robinson type 11.3
27 syndromic x-linked intellectual disability snyder type 11.3
28 bone disease 11.3
29 hyperparathyroidism 11.3
30 anorexia nervosa 11.2
31 bone fracture 11.2
32 cerebrotendinous xanthomatosis 11.2
33 severe congenital neutropenia 11.2
34 osteopetrosis 11.2
35 turner syndrome 11.2
36 graves' disease 11.2
37 cleft palate, isolated 11.2
38 cholangitis, primary sclerosing 11.2
39 acth-secreting pituitary adenoma 11.2
40 homocystinuria 11.2
41 epiphyseal dysplasia, multiple, with early-onset diabetes mellitus 11.1
42 multicentric osteolysis, nodulosis, and arthropathy 11.1
43 winchester syndrome 11.1
44 aromatase deficiency 11.1
45 premature aging syndrome, okamoto type 11.0
46 pituitary adenoma 4, acth-secreting 11.0
47 dyskeratosis congenita, autosomal recessive 1 11.0
48 hyaline fibromatosis syndrome 11.0
49 prader-willi habitus, osteopenia, and camptodactyly 11.0
50 osteogenesis imperfecta, type xii 11.0
51 dyskeratosis congenita, autosomal dominant 2 11.0
52 nestor-guillermo progeria syndrome 11.0
53 osteogenesis imperfecta, type xiii 11.0
54 dyskeratosis congenita, autosomal recessive 5 11.0
55 pigmented nodular adrenocortical disease, primary, 4 11.0
56 ehlers-danlos syndrome, classic-like, 2 11.0
57 cleidocranial dysplasia 10.9
58 dyskeratosis congenita, autosomal dominant 1 10.9
59 hyperparathyroidism 2 with jaw tumors 10.9
60 singleton-merten syndrome 1 10.9
61 cardiomyopathy, dilated, with hypergonadotropic hypogonadism 10.9
62 acth-independent macronodular adrenal hyperplasia 10.9
63 geroderma osteodysplasticum 10.9
64 achalasia-addisonianism-alacrima syndrome 10.9
65 growth hormone insensitivity with immunodeficiency 10.9
66 mucolipidosis iii alpha/beta 10.9
67 bruck syndrome 1 10.9
68 parana hard-skin syndrome 10.9
69 spondyloepimetaphyseal dysplasia, sponastrime type 10.9
70 dyskeratosis congenita, x-linked 10.9
71 kallmann syndrome with spastic paraplegia 10.9
72 menkes disease 10.9
73 stuve-wiedemann syndrome 10.9
74 spondyloocular syndrome 10.9
75 parathyroid carcinoma 10.9
76 pigmented nodular adrenocortical disease, primary, 2 10.9
77 pigmented nodular adrenocortical disease, primary, 1 10.9
78 osteogenesis imperfecta, type viii 10.9
79 dyskeratosis congenita, autosomal recessive 2 10.9
80 dyskeratosis congenita, autosomal recessive 3 10.9
81 dyskeratosis congenita, autosomal dominant 3 10.9
82 pigmented nodular adrenocortical disease, primary, 3 10.9
83 estrogen resistance 10.9
84 acth-independent macronodular adrenal hyperplasia 2 10.9
85 dyskeratosis congenita, autosomal recessive 6 10.9
86 dyskeratosis congenita, autosomal dominant 6 10.9
87 thrombocytopenia 6 10.9
88 ovarian dysgenesis 8 10.9
89 primary pigmented nodular adrenocortical disease 10.9
90 spinal disease 10.9
91 kallmann syndrome 10.9
92 47, xxy 10.9
93 atypical werner syndrome 10.9
94 congenital analbuminemia 10.9
95 familial isolated hyperparathyroidism 10.9
96 geroderma osteodysplastica 10.9
97 neonatal adrenoleukodystrophy 10.9
98 renal tubulopathy, diabetes mellitus, and cerebellar ataxia due to duplication of mitochondrial dna 10.9
99 singleton-merten syndrome 10.9
100 osteoarthritis 10.6
101 arthritis 10.6
102 rheumatoid arthritis 10.6
103 osteoporotic fracture 10.5
104 bone resorption disease 10.5
105 osteonecrosis 10.5
106 uruguay faciocardiomusculoskeletal syndrome 10.4
107 osteomalacia 10.4
108 breast cancer 10.4
109 osteonecrosis of the jaw 10.4
110 periodontal disease 10.4
111 aging 10.3
112 diabetes mellitus 10.3
113 thalassemia 10.3
114 mastocytosis 10.3
115 prostate cancer 10.3
116 prostate cancer, hereditary, 8 10.3
117 prostate cancer, hereditary, 6 10.3
118 primary biliary cholangitis 10.3
119 rheumatic disease 10.3
120 spondylitis 10.3
121 spondyloarthropathy 1 10.3
122 biliary cirrhosis, primary, 1 10.3
123 primary biliary cirrhosis 10.3
124 liver disease 10.2
125 inflammatory bowel disease 10.2
126 primary hyperparathyroidism 10.2
127 hypogonadism 10.2
128 hypogonadotropism 10.2
129 celiac disease 1 10.2
130 brittle bone disorder 10.2
131 col1a1/2-related osteogenesis imperfecta 10.2
132 periodontitis 10.2
133 systemic mastocytosis 10.2
134 mammary paget's disease 10.2
135 pulmonary disease, chronic obstructive 10.2
136 conn's syndrome 10.2
137 amenorrhea 10.2
138 bone mineral density quantitative trait locus 3 10.1
139 beta-thalassemia 10.1
140 kidney disease 10.1
141 vertigo, benign recurrent 10.1
142 insulin-like growth factor i 10.1
143 body mass index quantitative trait locus 1 10.1
144 chronic kidney failure 10.1
145 benign paroxysmal positional nystagmus 10.1
146 autoimmune disease 10.1
147 hepatitis 10.1
148 secondary hyperparathyroidism 10.1
149 dementia 10.1
150 muscular dystrophy 10.1
151 joint disorders 10.0
152 spinal cord injury 10.0
153 heart disease 10.0
154 depression 10.0
155 multiple sclerosis 10.0
156 cystic fibrosis 10.0
157 muscular dystrophy, duchenne type 10.0
158 psoriatic arthritis 10.0
159 cerebral palsy 10.0
160 liver cirrhosis 10.0
161 scoliosis 10.0
162 hemiplegia 10.0
163 arthropathy 10.0
164 paget's disease of bone 10.0
165 gastrointestinal system disease 10.0
166 hyperthyroidism 10.0
167 pemphigus 10.0
168 acroosteolysis 10.0
169 diabetes mellitus, noninsulin-dependent 10.0
170 autoimmune disease 1 10.0
171 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.0
172 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.0
173 crohn's disease 10.0
174 nephrolithiasis 10.0
175 neutropenia 10.0
176 vascular disease 10.0
177 spondylosis 10.0
178 connective tissue disease 10.0
179 eating disorder 10.0
180 alzheimer disease 10.0
181 systemic lupus erythematosus 10.0
182 schizophrenia 10.0
183 temporal arteritis 10.0
184 hypoascorbemia 10.0
185 asthma 10.0
186 cataract 10.0
187 osteomyelitis 10.0
188 hypoparathyroidism 10.0
189 hemosiderosis 10.0
190 hyperostosis 10.0
191 paraplegia 10.0
192 lupus erythematosus 10.0
193 fatty liver disease 10.0
194 irritable bowel syndrome 10.0
195 atherosclerosis susceptibility 9.9
196 neurofibromatosis, type iv, of riccardi 9.9
197 pemphigus vulgaris, familial 9.9
198 tetralogy of fallot 9.9
199 leukemia 9.9
200 pemphigus vulgaris 9.9
201 renal tubular acidosis 9.9
202 nonalcoholic fatty liver disease 9.9
203 hypogonadotropic hypogonadism 9.9
204 urticaria 9.9
205 hepatitis c 9.9
206 epidermolysis bullosa 9.9
207 human immunodeficiency virus infectious disease 9.9
208 adenoma 9.9
209 juvenile rheumatoid arthritis 9.9
210 muscular atrophy 9.9
211 periodontitis, chronic 9.9
212 graves disease 1 9.9
213 helicobacter pylori infection 9.9
214 xanthomatosis 9.9
215 homocysteinemia 9.9
216 coronary heart disease 1 9.9
217 leukemia, acute lymphoblastic 9.9
218 gastric cancer 9.9
219 pemphigus foliaceus 9.9
220 systemic scleroderma 9.9
221 lymphoma 9.9
222 siderosis 9.9
223 lymphocytic leukemia 9.9
224 lactose intolerance 9.9
225 nephrotic syndrome 9.9
226 otosclerosis 9.9
227 patulous eustachian tube 9.9
228 gout 9.9
229 ehlers-danlos syndrome 9.9
230 thyroid cancer 9.9
231 acromegaly 9.9
232 complex regional pain syndrome 9.9
233 bone inflammation disease 9.9
234 indolent systemic mastocytosis 9.9
235 pancreatitis 9.9
236 lung disease 9.9
237 cholangitis 9.9
238 bronchiectasis 9.9
239 autoimmune progesterone dermatitis 9.9
240 arteries, anomalies of 9.8
241 endosteal hyperostosis, autosomal dominant 9.8
242 mastocytosis, cutaneous 9.8
243 neurofibromatosis, type i 9.8
244 retinal detachment 9.8
245 scleroderma, familial progressive 9.8
246 triiodothyronine receptor auxiliary protein 9.8
247 hemochromatosis, type 1 9.8
248 hypogonadism, male 9.8
249 rett syndrome 9.8
250 hepatitis c virus 9.8
251 alopecia 9.8
252 epidermolysis bullosa dystrophica 9.8
253 hepatitis b 9.8
254 colitis 9.8
255 uveitis 9.8
256 cholestasis 9.8
257 hypothyroidism 9.8
258 calcinosis 9.8
259 epilepsy 9.8
260 impotence 9.8
261 iron metabolism disease 9.8
262 dermatitis 9.8
263 lipid metabolism disorder 9.8
264 pustulosis of palm and sole 9.8
265 bronchitis 9.8
266 psoriasis 9.8
267 juvenile hereditary hemochromatosis 9.8
268 rere-related disorders 9.8
269 growth hormone deficiency 9.8
270 differentiated thyroid carcinoma 9.8
271 rapidly involuting congenital hemangioma 9.8
272 idiopathic hypercalciuria 9.8
273 alcohol dependence 9.7
274 gastroesophageal reflux 9.7
275 hyperostosis frontalis interna 9.7
276 marfan syndrome 9.7
277 migraine with or without aura 1 9.7
278 paget disease of bone 3 9.7
279 prader-willi syndrome 9.7
280 scheuermann disease 9.7
281 scoliosis, isolated 1 9.7
282 spondylolisthesis 9.7
283 spondylosis, cervical 9.7
284 down syndrome 9.7
285 adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency 9.7
286 persistent hyperplastic primary vitreous, autosomal recessive 9.7
287 myasthenia gravis 9.7
288 myeloma, multiple 9.7
289 osteogenic sarcoma 9.7
290 shwachman-diamond syndrome 1 9.7
291 mend syndrome 9.7
292 arts syndrome 9.7
293 pituitary adenoma, prolactin-secreting 9.7
294 stroke, ischemic 9.7
295 horns in sheep 9.7
296 acute insulin response 9.7
297 dermatitis, atopic 9.7
298 reflex sympathetic dystrophy 9.7
299 bulimia nervosa 9.7
300 anxiety 9.7
301 bestrophinopathy, autosomal recessive 9.7
302 microvascular complications of diabetes 3 9.7
303 microvascular complications of diabetes 4 9.7
304 microvascular complications of diabetes 6 9.7
305 microvascular complications of diabetes 7 9.7
306 infantile liver failure syndrome 1 9.7
307 global developmental delay, absent or hypoplastic corpus callosum, and dysmorphic facies 9.7
308 alcohol abuse 9.7
309 autoimmune hepatitis 9.7
310 brain injury 9.7
311 burns 9.7
312 end stage renal failure 9.7
313 ischemic heart disease 9.7
314 muscle disorders 9.7
315 polycystic ovary syndrome 9.7
316 pseudoarthrosis 9.7
317 pulmonary emphysema 9.7
318 silicosis 9.7
319 spinal stenosis 9.7
320 thrombocytopenia 9.7
321 traumatic brain injury 9.7
322 chlamydia pneumonia 9.7
323 hypophosphatemia 9.7
324 exudative vitreoretinopathy 9.7
325 sleep apnea 9.7
326 idiopathic scoliosis 9.7
327 myelomeningocele 9.7
328 recessive dystrophic epidermolysis bullosa 9.7
329 sensorineural hearing loss 9.7
330 dermatomyositis 9.7
331 premature menopause 9.7
332 cholesteatoma of middle ear 9.7
333 spondyloarthropathy 9.7
334 vitamin k deficiency bleeding 9.7
335 chlamydia 9.7
336 allergic hypersensitivity disease 9.7
337 nephrocalcinosis 9.7
338 renal osteodystrophy 9.7
339 algoneurodystrophy 9.7
340 gaucher's disease 9.7
341 psychotic disorder 9.7
342 acute pancreatitis 9.7
343 testicular cancer 9.7
344 substance abuse 9.7
345 osteitis fibrosa 9.7
346 hyperglycemia 9.7
347 myopathy 9.7
348 rhinitis 9.7
349 diffuse idiopathic skeletal hyperostosis 9.7
350 peptic ulcer disease 9.7
351 herpes zoster 9.7
352 hypopituitarism 9.7
353 bowenoid papulosis 9.7
354 hemophilic arthropathy 9.7
355 myasthenia gravis congenital 9.7
356 polymyositis 9.7
357 splenomegaly 9.7
358 hypoxia 9.7
359 pain - chronic 9.7
360 amyotrophic lateral sclerosis 1 9.6
361 bladder cancer 9.6
362 blood group, langereis system 9.6
363 colorectal cancer 9.6
364 coloboma of macula 9.6
365 multiple endocrine neoplasia, type i 9.6
366 developmental dysplasia of the hip 1 9.6
367 renal cell carcinoma, nonpapillary 9.6
368 hypertension, essential 9.6
369 hypertriglyceridemia, familial 9.6
370 hypogonadotropic hypogonadism 7 with or without anosmia 9.6
371 multiple system atrophy 1 9.6
372 inclusion body myositis 9.6
373 jacobsen syndrome 9.6
374 moebius syndrome 9.6
375 myelopathy, htlv-1-associated 9.6
376 myositis 9.6
377 nephrolithiasis, calcium oxalate 9.6
378 papillomatosis, confluent and reticulated 9.6
379 pernicious anemia 9.6
380 pityriasis rubra pilaris 9.6
381 mccune-albright syndrome 9.6
382 hutchinson-gilford progeria syndrome 9.6
383 protoporphyria, erythropoietic, 1 9.6
384 protrusio acetabuli 9.6
385 retinoblastoma 9.6
386 sarcoidosis 1 9.6
387 neural tube defects 9.6
388 trigeminal neuralgia 9.6
389 von hippel-lindau syndrome 9.6
390 lipoid congenital adrenal hyperplasia 9.6
391 neuropathy, hereditary sensory and autonomic, type iii 9.6
392 renal glucosuria 9.6
393 lymphoma, hodgkin, classic 9.6
394 familial mediterranean fever 9.6
395 neuroblastoma 1 9.6
396 gyrate atrophy of choroid and retina 9.6
397 osteoid osteoma 9.6
398 laron syndrome 9.6
399 pituitary hormone deficiency, combined, 2 9.6
400 pycnodysostosis 9.6
401 taurodontism 9.6
402 alopecia, congenital 9.6
403 body mass index quantitative trait locus 11 9.6
404 hypophosphatemic rickets, x-linked recessive 9.6
405 fabry disease 9.6
406 lowe oculocerebrorenal syndrome 9.6
407 oncocytoma 9.6
408 gonadal agenesis 9.6
409 yemenite deaf-blind hypopigmentation syndrome 9.6
410 hemochromatosis, type 2a 9.6
411 macular degeneration, age-related, 1 9.6
412 body mass index quantitative trait locus 8 9.6
413 sickle cell anemia 9.6
414 salla disease 9.6
415 langerhans cell histiocytosis 9.6
416 lymphoma, non-hodgkin, familial 9.6
417 genitopatellar syndrome 9.6
418 allergic rhinitis 9.6
419 headache associated with sexual activity 9.6
420 body mass index quantitative trait locus 10 9.6
421 endometrial cancer 9.6
422 body mass index quantitative trait locus 7 9.6
423 myocardial infarction 9.6
424 carney complex variant 9.6
425 aplastic anemia 9.6
426 human immunodeficiency virus type 1 9.6
427 osteogenesis imperfecta, type v 9.6
428 deafness-infertility syndrome 9.6
429 glass syndrome 9.6
430 body mass index quantitative trait locus 14 9.6
431 porphyria, acute hepatic 9.6
432 premature ovarian failure 7 9.6
433 alpha-1-antitrypsin deficiency 9.6
434 muscle hypertrophy 9.6
435 microcephaly, epilepsy, and diabetes syndrome 9.6
436 graft-versus-host disease 9.6
437 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 9.6
438 leptin receptor deficiency 9.6
439 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 9.6
440 body mass index quantitative trait locus 18 9.6
441 alacrima, achalasia, and mental retardation syndrome 9.6
442 sacral agenesis with vertebral anomalies 9.6
443 blood group, gerbich system 9.6
444 body mass index quantitative trait locus 19 9.6
445 peripheral vascular disease 9.6
446 deficiency anemia 9.6
447 kashin-beck disease 9.6
448 acute liver failure 9.6
449 acute lymphoblastic leukemia, childhood 9.6
450 alcoholic liver cirrhosis 9.6
451 chronic inflammatory demyelinating polyneuropathy 9.6
452 colorectal adenoma 9.6
453 common variable immunodeficiency 9.6
454 congestive heart failure 9.6
455 coronary artery anomaly 9.6
456 degenerative disc disease 9.6
457 dentinogenesis imperfecta 9.6
458 fecal incontinence 9.6
459 gingival recession 9.6
460 glomerulonephritis 9.6
461 glycogen storage disease 9.6
462 hemangioma 9.6
463 hematopoietic stem cell transplantation 9.6
464 hydrocephalus 9.6
465 ichthyosis lamellar 1 9.6
466 intermittent claudication 9.6
467 osteochondrosis 9.6
468 pulmonary fibrosis 9.6
469 renal oncocytoma 9.6
470 spinal muscular atrophy 9.6
471 ulcerative colitis 9.6
472 wrinkles 9.6
473 hyperphosphatemia 9.6
474 loeys-dietz syndrome 9.6
475 brachydactyly 9.6
476 metabolic acidosis 9.6
477 peripheral artery disease 9.6
478 paraphilia disorder 9.6
479 microscopic colitis 9.6
480 atrial fibrillation 9.6
481 persistent hyperplastic primary vitreous 9.6
482 parietal foramina 9.6
483 fibrous dysplasia 9.6
484 stickler syndrome 9.6
485 superior semicircular canal dehiscence 9.6
486 hemochromatosis type 2 9.6
487 corneal disease 9.6
488 dry eye syndrome 9.6
489 cholelithiasis 9.6
490 pre-eclampsia 9.6
491 microphthalmia 9.6
492 lepromatous leprosy 9.6
493 transsexualism 9.6
494 hydronephrosis 9.6
495 sarcoma 9.6
496 respiratory failure 9.6
497 chondrocalcinosis 9.6
498 infant gynecomastia 9.6
499 iron deficiency anemia 9.6
500 postmenopausal atrophic vaginitis 9.6
501 tarsal tunnel syndrome 9.6
502 gynecomastia 9.6
503 guillain-barre syndrome 9.6
504 sialolithiasis 9.6
505 eclampsia 9.6
506 schistosomiasis 9.6
507 ochronosis 9.6
508 adult-onset still's disease 9.6
509 sclerosing cholangitis 9.6
510 46 xx gonadal dysgenesis 9.6
511 labyrinthitis 9.6
512 disease of mental health 9.6
513 personality disorder 9.6
514 angioedema 9.6
515 thrombocytopenia due to platelet alloimmunization 9.6
516 pneumothorax 9.6
517 neuroendocrine tumor 9.6
518 ichthyosis 9.6
519 neuritis 9.6
520 hyperuricemia 9.6
521 exostosis 9.6
522 post-traumatic stress disorder 9.6
523 dental caries 9.6
524 vaginitis 9.6
525 ankylosis 9.6
526 lateral sclerosis 9.6
527 arteriosclerosis 9.6
528 bruxism 9.6
529 adenocarcinoma 9.6
530 interstitial lung disease 9.6
531 cutis laxa 9.6
532 tropical spastic paraparesis 9.6
533 lipid pneumonia 9.6
534 ischemia 9.6
535 purpura 9.6
536 histiocytosis 9.6
537 mixed connective tissue disease 9.6
538 superior mesenteric artery syndrome 9.6
539 empty sella syndrome 9.6
540 gastric adenocarcinoma 9.6
541 pituitary adenoma 9.6
542 gastritis 9.6
543 pseudohypoparathyroidism 9.6
544 carcinosarcoma 9.6
545 radiculopathy 9.6
546 polyradiculoneuropathy 9.6
547 neuromuscular disease 9.6
548 macular retinal edema 9.6
549 persian gulf syndrome 9.6
550 hypokalemia 9.6
551 atrophic rhinitis 9.6
552 calciphylaxis 9.6
553 poliomyelitis 9.6
554 chronic inflammatory demyelinating polyradiculoneuropathy 9.6
555 infertility 9.6
556 intestinal disease 9.6
557 pneumonia 9.6
558 adenosine deaminase deficiency 9.6
559 epithelioid sarcoma 9.6
560 fibromyalgia 9.6
561 acquired immunodeficiency syndrome 9.6
562 inherited metabolic disorder 9.6
563 adrenal adenoma 9.6
564 kummell's disease 9.6
565 monoclonal gammopathy of uncertain significance 9.6
566 septic arthritis 9.6
567 influenza 9.6
568 vasculitis 9.6
569 fascioliasis 9.6
570 atrophic gastritis 9.6
571 amyloidosis 9.6
572 meningitis 9.6
573 postpartum depression 9.6
574 fasciitis 9.6
575 necrotizing fasciitis 9.6
576 alopecia areata 9.6
577 hypervitaminosis d 9.6
578 hemophilia 9.6
579 microcephaly 9.6
580 isolated gonadotropin-releasing hormone deficiency 9.6
581 aminoaciduria 9.6
582 anterior uveitis 9.6
583 cervical intraepithelial neoplasia 9.6
584 chiari malformation 9.6
585 chronic graft versus host disease 9.6
586 congenital hydrocephalus 9.6
587 cytokine deficiency 9.6
588 glossodynia 9.6
589 heparin-induced thrombocytopenia 9.6
590 hyperadrenalism 9.6
591 idiopathic neutropenia 9.6
592 lathyrism 9.6
593 lymphangiectasis 9.6
594 renal tubular acidosis, distal 9.6
595 sickle beta thalassemia 9.6
596 spastic paraparesis 9.6
597 spondylarthropathy 9.6
598 spondyloenchondrodysplasia 9.6
599 streptococcal group a invasive disease 9.6
600 sudden sensorineural hearing loss 9.6
601 synovial chondromatosis 9.6
602 multiple endocrine neoplasia 9.6
603 spasticity 9.6
604 syncope 9.6
605 cytomegalovirus infection 9.6
606 dysautonomia 9.6
607 familial calcium pyrophosphate deposition 9.6
608 eosinophilic colitis 9.6
609 idiopathic avascular necrosis 9.6
610 autoimmune hypoparathyroidism 9.6
611 moderate and severe traumatic brain injury 9.6

Graphical network of the top 20 diseases related to Bone Mineral Density Quantitative Trait Locus 8:



Diseases related to Bone Mineral Density Quantitative Trait Locus 8

Symptoms & Phenotypes for Bone Mineral Density Quantitative Trait Locus 8

Clinical features from OMIM:

611739

UMLS symptoms related to Bone Mineral Density Quantitative Trait Locus 8:


tremor, angina pectoris, back pain, sciatica, equilibration disorder, muscle cramp, pelvic pain

Drugs & Therapeutics for Bone Mineral Density Quantitative Trait Locus 8

Drugs for Bone Mineral Density Quantitative Trait Locus 8 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 15, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
2 Protective Agents Phase 3
3 Antioxidants Phase 3
4 Trace Elements Phase 3
5 Sodium Selenite Phase 3
6 Micronutrients Phase 3
7 Nutrients Phase 3
8
Benzocaine Approved, Investigational Not Applicable 1994-09-7, 94-09-7 2337
9
tannic acid Approved Not Applicable 1401-55-4
10
Calcium Approved, Nutraceutical Not Applicable 7440-70-2 271
11
Vitamin D Approved, Nutraceutical, Vet_approved Not Applicable 1406-16-2
12 Calciferol Not Applicable
13 Vitamins Not Applicable
14 Caseins Not Applicable
15 Calcium, Dietary Not Applicable

Interventional clinical trials:

(showing 5, show less)
# Name Status NCT ID Phase Drugs
1 Selenium for Musculoskeletal Health Active, not recruiting NCT02832648 Phase 3
2 DeFRA Questionnaire as an Anamnestic Form Completed NCT02003716
3 Nutritional Supplement and Bone Health in Post-Menopausal Women Recruiting NCT03337971 Not Applicable
4 Milk Protein and Bone Health in Postmenopausal Women Recruiting NCT03701113 Not Applicable
5 Radio-frequency Identification (RFID) Osteoporosis Pilot Study Not yet recruiting NCT03385941

Search NIH Clinical Center for Bone Mineral Density Quantitative Trait Locus 8

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Bone Mineral Density Quantitative Trait Locus 8

Anatomical Context for Bone Mineral Density Quantitative Trait Locus 8

MalaCards organs/tissues related to Bone Mineral Density Quantitative Trait Locus 8:

42
Bone, Liver, Kidney, Bone Marrow, Breast, Prostate, Pituitary

Publications for Bone Mineral Density Quantitative Trait Locus 8

Articles related to Bone Mineral Density Quantitative Trait Locus 8:

(showing 2981, show less)
# Title Authors Year
1
Bmi1 Overexpression in Mesenchymal Stem Cells Exerts Anti-Aging and Anti-Osteoporosis Effects by Inactivating p16/p19 Signaling And Inhibiting Oxidative Stress. ( 30895687 )
2019
2
Hydroxytyrosol protects from aging process via AMPK and autophagy; a review of its effects on cancer, metabolic syndrome, osteoporosis, immune-mediated and neurodegenerative diseases. ( 30853597 )
2019
3
Opportunistic screening for osteoporosis using thoraco-abdomino-pelvic CT-scan assessing the vertebral density in rheumatoid arthritis patients. ( 30868182 )
2019
4
Osteoporosis, Childhood Bullying, Rheumatoid Arthritis, Diabetes Counseling, Inhaled Steroids. ( 30874411 )
2019
5
Evaluation of the implementation of guidelines on the treatment of osteoporosis in patients with rheumatoid arthritis. ( 30877214 )
2019
6
Correlation between systemic osteoporosis and local bone erosion with rheumatoid arthritis patients in Chinese population. ( 30847477 )
2019
7
Conventional synthetic disease-modifying antirheumatic drugs and bone mineral density in rheumatoid arthritis patients with osteoporosis: possible beneficial effect of leflunomide. ( 30767868 )
2019
8
Calcium and vitamin D supplementation with 3-year denosumab treatment is beneficial to enhance bone mineral density in postmenopausal patients with osteoporosis and rheumatoid arthritis. ( 30588001 )
2019
9
Association of Bone Metastasis With Early-Stage Breast Cancer in Women With and Without Precancer Osteoporosis According to Osteoporosis Therapy Status. ( 30848812 )
2019
10
Oxygen desaturation during the 6-min walk test as a risk for osteoporosis in non-cystic fibrosis bronchiectasis. ( 30717716 )
2019
11
Association Between Cataract and Risks of Osteoporosis and Fracture: A Nationwide Cohort Study. ( 30281143 )
2019
12
Incidence of osteoarthritis, osteoporosis and inflammatory musculoskeletal diseases in adults with cerebral palsy: A population-based cohort study. ( 31075418 )
2019
13
Adults With Cerebral Palsy Have Higher Prevalence of Fracture Compared With Adults Without Cerebral Palsy Independent of Osteoporosis and Cardiometabolic Diseases. ( 30730595 )
2019
14
Severe hypocalcemia following denosumab treatment in a patient with secondary osteoporosis associated with primary sclerosing cholangitis. ( 30713246 )
2019
15
Colorectal Cancer, Osteoporosis, Knee Osteoarthritis, Suspected Dementia, Pacifier Use. ( 30990293 )
2019
16
Cognition and Vitamin D in Older African-American Women- Physical performance and Osteoporosis prevention with vitamin D in older African Americans Trial and Dementia. ( 30359476 )
2019
17
Atopic dermatitis is associated with osteoporosis and osteopenia in older adults. ( 29800580 )
2019
18
Osteoporosis and vertebral fracture are associated with deterioration of activities of daily living and quality of life in patients with type 2 diabetes mellitus. ( 30191456 )
2019
19
Retrospective longitudinal study of osteoporosis in adults with recessive dystrophic epidermolysis bullosa. ( 30656009 )
2019
20
Necrotizing fasciitis as a complication of osteonecrosis of the jaw related to oral bisphosphonate application in a patient with osteoporosis: a case report. ( 30288621 )
2019
21
Increased Risk of Osteoporosis in Gastric Cancer Survivors Compared to General Population Control: A Study with Representative Korean Population. ( 29986577 )
2019
22
Pro-inflammatory Cytokines: Cellular and Molecular Drug Targets for Glucocorticoid-induced-osteoporosis via Osteocyte. ( 29618305 )
2019
23
Prevention of Glucocorticoid-Induced Osteoporosis: Clinical audit to evaluate the implementation of National Osteoporosis Guideline Group 2017 guidelines in a primary care setting. ( 29729949 )
2019
24
Glucocorticoid-Induced Osteoporosis: Management Challenges in Older Patients. ( 29941355 )
2019
25
Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs. ( 30187273 )
2019
26
Luteolin attenuates glucocorticoid-induced osteoporosis by regulating ERK/Lrp-5/GSK-3β signaling pathway in vivo and in vitro. ( 30192012 )
2019
27
Osteoblast autophagy in glucocorticoid-induced osteoporosis. ( 30417506 )
2019
28
The prevention of glucocorticoid-induced osteoporosis in patients with immune thrombocytopenia receiving steroids: a British Society for Haematology Good Practice Paper. ( 30609018 )
2019
29
Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan. ( 30610244 )
2019
30
Metabolomics Profiling Reveals Rehmanniae Radix Preparata Extract Protects against Glucocorticoid-Induced Osteoporosis Mainly via Intervening Steroid Hormone Biosynthesis. ( 30641909 )
2019
31
Glucocorticoid-Induced Osteoporosis: New Insights into the Pathophysiology and Treatments. ( 30685820 )
2019
32
Metabolomics profiling provides valuable insights into the underlying mechanisms of Morinda officinalis on protecting glucocorticoid-induced osteoporosis. ( 30690247 )
2019
33
Osteoprotective Effect of Cimiracemate in Glucocorticoid-Induced Osteoporosis by Osteoprotegerin/Receptor Activator of Nuclear Factor κ B/Receptor Activator of Nuclear Factor Kappa-Β Ligand Signaling. ( 30695776 )
2019
34
Preventative effects of metformin on glucocorticoid-induced osteoporosis in rats. ( 30706148 )
2019
35
Glucocorticoid-induced osteoporosis preventive care in rheumatology patients. ( 30723883 )
2019
36
Glucocorticoid-induced osteoporosis: 2019 concise clinical review. ( 30805679 )
2019
37
Denosumab vs risedronate in glucocorticoid-induced osteoporosis: final results of a 24-month randomized, double-blind, double-dummy trial. ( 30816640 )
2019
38
Z-Guggulsterone attenuates glucocorticoid-induced osteoporosis through activation of Nrf2/HO-1 signaling. ( 30905781 )
2019
39
Glucocorticoid-Induced Osteoporosis. ( 30943350 )
2019
40
Glucocorticoid-Induced Osteoporosis. Reply. ( 30943351 )
2019
41
Liraglutide increases bone formation and inhibits bone resorption in rats with glucocorticoid-induced osteoporosis. ( 30955181 )
2019
42
Glucocorticoid-induced osteoporosis update. ( 31045947 )
2019
43
Glucocorticoid induced osteoporosis. ( 31094232 )
2019
44
Correction to: Bisphosphonate therapy for spinal osteoporosis in Hajdu-Cheney syndrome - new data and literature review. ( 31077240 )
2019
45
The association between hepatitis and osteoporosis: a nested case-control study using a national sample cohort. ( 30852676 )
2019
46
Antiviral therapy and the development of osteopenia/osteoporosis among Asians with chronic hepatitis B. ( 30776311 )
2019
47
Herpes zoster and the risks of osteoporosis and fracture: a nationwide cohort study. ( 30460416 )
2019
48
Tetrahydroxy stilbene glucoside protected against diabetes-induced osteoporosis in mice with streptozotocin-induced hyperglycemia. ( 30456807 )
2019
49
Predictors of nephrolithiasis, osteoporosis and mortality in primary hyperparathyroidism. ( 30916764 )
2019
50
Exercise Alleviates Osteoporosis in Rats with Mild Chronic Kidney Disease by Decreasing Sclerostin Production. ( 31027235 )
2019
51
Correlation of the severity of chronic kidney disease with serum inflammation, osteoporosis and vitamin D deficiency. ( 30651805 )
2019
52
The Effect of Alcohol Dehydrogenase Isozymes on Alcoholic Liver Disease and Alcoholic Osteoporosis. ( 30918159 )
2019
53
World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2019): Committee of National Societies Abstracts. ( 31101950 )
2019
54
Recommendations for the Reporting of Harms in Manuscripts on Clinical Trials Assessing Osteoarthritis Drugs: A Consensus Statement from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). ( 31073927 )
2019
55
Assessment of Muscle Function and Physical Performance in Daily Clinical Practice : A position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). ( 30972475 )
2019
56
Practical guidance for engaging patients in health research, treatment guidelines and regulatory processes: results of an expert group meeting organized by the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). ( 30993659 )
2019
57
Impact of comorbidity rates of lumbar spondylosis, knee osteoarthritis, and osteoporosis on physical QOL and risk factors for poor physical QOL in middle-aged and elderly people. ( 30924379 )
2019
58
Sirtuins and FoxOs in osteoporosis and osteoarthritis. ( 30738214 )
2019
59
Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts' consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. ( 30382319 )
2019
60
Clinical effect of early bisphosphonate treatment for pyogenic vertebral osteomyelitis with osteoporosis: An analysis by the Cox proportional hazard model. ( 30172897 )
2019
61
Incidence of osteonecrosis of the jaw in Japanese osteoporosis patients taking minodronic acid. ( 30719580 )
2019
62
Osteoporosis therapy in patients with inflammatory rheumatic diseases and osteonecrosis of the jaw. ( 30796524 )
2019
63
Puerarin alleviates streptozotocin (STZ)-induced osteoporosis in rats through suppressing inflammation and apoptosis via HDAC1/HDAC3 signaling. ( 31054509 )
2019
64
Hexapeptide-conjugated calcitonin for targeted therapy of osteoporosis. ( 31054990 )
2019
65
Insight into the possible role of miR-214 in primary osteoporosis via osterix. ( 31056782 )
2019
66
Comprehensive circular RNA profiling reveals circ_0002060 as a potential diagnostic biomarkers for osteoporosis. ( 31056800 )
2019
67
Molecular understanding of pharmacological treatment of osteoporosis. ( 31057953 )
2019
68
Knowledge gap regarding osteoporosis among medical professionals in Southern India. ( 31062414 )
2019
69
Medical Treatment for Osteoporosis: From Molecular to Clinical Opinions. ( 31064048 )
2019
70
Current Status of Bone-Forming Therapies for the Management of Osteoporosis. ( 31066015 )
2019
71
The prevalence of osteoporosis in China, a nationwide, multicenter DXA survey. ( 31067339 )
2019
72
Osteoporosis and Sarcopenia Increase Frailty Syndrome in the Elderly. ( 31068903 )
2019
73
Longitudinal assessment of health-related quality of life in osteoporosis: data from the population-based Canadian Multicentre Osteoporosis Study. ( 31069440 )
2019
74
Nanoparticles to Knockdown Osteoporosis-Related Gene and Promote Osteogenic Markers Expression for Osteoporosis Treatment. ( 31071265 )
2019
75
PTH 1-34 Loaded Thiolated Chitosan Nanoparticles for Osteoporosis: Oral Bioavailability and Anabolic Effect on Primary Osteoblast Cells (Journal of Biomedical Nanotechnology, Vol. 10(1), pp. 166-178 (2014)). ( 31072442 )
2019
76
Long Noncoding RNA Analyses for Osteoporosis Risk in Caucasian Women. ( 31073748 )
2019
77
An update on therapies for the treatment of diabetes-induced osteoporosis. ( 31079501 )
2019
78
Association of P2X7R gene with serum lipid profiles in Chinese postmenopausal women with osteoporosis. ( 31079509 )
2019
79
Clinical effect observation of intravenous application of zoledronic acid in patients with cervical spondylosis and osteoporosis after anterior cervical discectomy and fusion: A randomized controlled study. ( 31079567 )
2019
80
MOTS-c improves osteoporosis by promoting the synthesis of type I collagen in osteoblasts via TGF-β/SMAD signaling pathway. ( 31081069 )
2019
81
Comparative proteomics analysis of microvesicles in human serum for the evaluation of osteoporosis. ( 31081149 )
2019
82
Evaluation of screening practices for low bone mass and prevalence of osteoporosis and fractures in people living with HIV attending a sexual health clinic. ( 31081166 )
2019
83
Hydrogen gas protects against ovariectomy-induced osteoporosis by inhibiting NF-κB activation. ( 31083022 )
2019
84
OsteoporosAtlas: a human osteoporosis-related gene database. ( 31086734 )
2019
85
Rabbit as model for osteoporosis research. ( 31087186 )
2019
86
Biomechanical role of osteoporosis affects the incidence of adjacent segment disease after percutaneous transforaminal endoscopic discectomy. ( 31088476 )
2019
87
The evolving role of anabolic therapy in the treatment of osteoporosis. ( 31090588 )
2019
88
Bazedoxifene for the treatment of osteoporosis. ( 31091133 )
2019
89
Treatment of the surgical neck fracture of the humerus with a novel external fixator in the elderly with osteoporosis: biomechanical analysis. ( 31092231 )
2019
90
Sp1 Binding Site Polymorphism at COL1A1 Gene and Its Relation to Bone Mineral Density for Osteoporosis Risk Factor Among the Sikkimese Men and Women of Northeast India. ( 31092999 )
2019
91
Letter to the Editor: "Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline". ( 31095312 )
2019
92
Predictors of imminent non-vertebral fracture in elderly women with osteoporosis, low bone mass, or a history of fracture, based on data from the population-based Canadian Multicentre Osteoporosis Study (CaMos). ( 31098708 )
2019
93
Osteoporosis and Osteopenia Among Patients With Type 2 Diabetes Aged ≥50: Role of Sex and Clinical Characteristics. ( 31101413 )
2019
94
A pharmacist-run anabolic osteoporosis clinic: An abaloparatide descriptive report. ( 31101442 )
2019
95
Synthesis and structure-activity relationship of 4-alkoxy-thieno[2,3-b]pyridine derivatives as potent alkaline phosphatase enhancers for osteoporosis treatment. ( 31101474 )
2019
96
Methylglyoxal activates osteoclasts through JNK pathway leading to osteoporosis. ( 31103701 )
2019
97
Relationship between senile osteoporosis and cardiovascular and cerebrovascular diseases. ( 31105781 )
2019
98
Muscle-bone crosstalk and potential therapies for sarco-osteoporosis. ( 31106446 )
2019
99
The role of resveratrol in bone marrow-derived mesenchymal stem cells from patients with osteoporosis. ( 31106448 )
2019
100
Tanshinone prevents alveolar bone loss in ovariectomized osteoporosis rats by up-regulating phosphoglycerate dehydrogenase. ( 31108107 )
2019
101
Caution With New Osteoporosis Drug. ( 31112246 )
2019
102
Systemic sclerostin antibody treatment increases osseointegration and biomechanical competence of zoledronic-acid-coated dental implants in a rat osteoporosis model. ( 31112281 )
2019
103
Osteoporosis risk assessment using multilayered gold-nanoparticle thin film via SALDI-MS measurement. ( 30931506 )
2019
104
Abnormal sub-pathways competitively regulated by lncRNAs contribute to postmenopausal osteoporosis. ( 30936959 )
2019
105
Prioritization of candidate metabolites for postmenopausal osteoporosis using multi-omics composite network. ( 30936988 )
2019
106
Long noncoding RNAs: a missing link in osteoporosis. ( 30937214 )
2019
107
Factors affecting willingness to get assessed and treated for osteoporosis. ( 30944954 )
2019
108
Two-thirds of all fractures are not attributable to osteoporosis and advancing age: implication for fracture prevention. ( 30951170 )
2019
109
The aqueous and methanol extracts of Bambusa vulgaris (Poaceae) improve calcium and phosphorus levels, and bone microstructure in ovariectomized model of osteoporosis. ( 30951500 )
2019
110
Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis. ( 30953114 )
2019
111
The effect of educational text message based on health belief model on osteoporosis preventive behaviors in women: a randomized controlled clinical trial. ( 30955478 )
2019
112
Comparison of the effect of vitamin D on osteoporosis and osteoporotic patients with healthy individuals referred to the Bone Density Measurement Center. ( 30956224 )
2019
113
Platelet/lymphocyte ratio is an independent predictor for osteoporosis. ( 30957129 )
2019
114
Hypercholesterolaemia increases the risk of high‑turnover osteoporosis in men. ( 30957178 )
2019
115
Current and emerging osteoporosis pharmacotherapy for women: state of the art therapies for preventing bone loss. ( 30958709 )
2019
116
Prevalence of osteopenia, osteoporosis and their risk factors in the Niterói Family Doctor Program. ( 30958949 )
2019
117
Glucagon like peptide 2 has a positive impact on osteoporosis in ovariectomized rats. ( 30959027 )
2019
118
The Association between Osteoporosis and Grip Strength and Skeletal Muscle Mass in Community-Dwelling Older Women. ( 30959864 )
2019
119
Current Progress on MicroRNA-Based Gene Delivery in the Treatment of Osteoporosis and Osteoporotic Fracture. ( 30962808 )
2019
120
Differing impact of clinical factors on the risk of fracture in younger and older women in the general population and an osteoporosis clinic population. ( 30963310 )
2019
121
Drug efficacies on bone mineral density and fracture rate for the treatment of postmenopausal osteoporosis: a network meta-analysis. ( 30964193 )
2019
122
Lack of association between dietary inflammatory index and low impact fractures in the Brazilian population: the Brazilian Osteoporosis Study (BRAZOS). ( 30971320 )
2019
123
Facile preparation of a Ca(ii) carboxymethyl cellulose complex with enhanced calcium bioavailability for treatment of osteoporosis. ( 30972392 )
2019
124
Men's perceptions of living with osteoporosis: a systematic review of qualitative studies. ( 30975600 )
2019
125
The therapeutic effect of secretome from human umbilical cord-derived mesenchymal stem cells in age-related osteoporosis. ( 30977425 )
2019
126
Biological secondary contributors to osteoporosis in fractured patients, is an early systematic assay relevant? ( 30978416 )
2019
127
State of the art in osteoporosis risk assessment and treatment. ( 30980341 )
2019
128
The genetic architecture of osteoporosis and fracture risk. ( 30980960 )
2019
129
Measurement of Forearm Bone Density by Dual Energy X-Ray Absorptiometry Increases the Prevalence of Osteoporosis in Men With Celiac Disease. ( 30981003 )
2019
130
Surgeon Management of Osteoporosis in Instrumented Spine Surgery: AOSpine Latin America Survey. ( 30984496 )
2019
131
Evaluation of the tibial cortical thickness accuracy in osteoporosis diagnosis in comparison with dual energy X-ray absorptiometry. ( 30984666 )
2019
132
Osteoporosis Circumscripta on 68Ga-DOTATATE PET CT. ( 30985430 )
2019
133
Acupuncture for primary osteoporosis: A network meta-analysis of randomized controlled trials protocol. ( 30985666 )
2019
134
Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. ( 30987990 )
2019
135
Author Correction: An atlas of genetic influences on osteoporosis in humans and mice. ( 30988516 )
2019
136
Establishment of an osteoporosis model in tree shrews by bilateral ovariectomy and comprehensive evaluation. ( 30988748 )
2019
137
Identification of association between rs1057317 polymorphism in TLR4 3'-untranslated region and the susceptibility to osteoporosis. ( 30989725 )
2019
138
Lack of Transparency in the Meta-Analyses of Dietary and Urinary Sodium and Bone Mineral Density or Risk of Osteoporosis: A Letter to the Journal. ( 30990773 )
2019
139
Osteoporosis Is Common and Undertreated Prior to Total Joint Arthroplasty. ( 30992237 )
2019
140
Cost-effectiveness of antiosteoporosis strategies for postmenopausal women with osteoporosis in China. ( 30994577 )
2019
141
EXPOSURE TO FAMINE IN EARLY LIFE AND THE RISK OF OSTEOPOROSIS IN ADULTHOOD: A PROSPECTIVE STUDY. ( 30995429 )
2019
142
Calcium isotope ratios in blood and urine: A new biomarker for the diagnosis of osteoporosis. ( 30997369 )
2019
143
Letter to the Editor "Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline." ( 30998233 )
2019
144
Response to Letter to the Editor: Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. ( 30998238 )
2019
145
A Clinical Study of a Standardized Extract of Leaves of Dalbergia sissoo (Roxb ex DC) in Postmenopausal Osteoporosis. ( 31001055 )
2019
146
Editor's Comment on - "A Clinical Study of a Standardized Extract of Leaves of Dalbergia sissoo (Roxb ex DC) in Postmenopausal Osteoporosis". ( 31001056 )
2019
147
Advanced Genetic Approaches in Discovery and Characterization of Genes Involved With Osteoporosis in Mouse and Human. ( 31001327 )
2019
148
Microbial osteoporosis: The interplay between the gut microbiota and bones via host metabolism and immunity. ( 31001921 )
2019
149
The Endocannabinoid/Endovanilloid System in Bone: From Osteoporosis to Osteosarcoma. ( 31003519 )
2019
150
NIPA2 regulates osteoblast function via its effect on apoptosis pathways in type 2 diabetes osteoporosis. ( 31003774 )
2019
151
Preliminary studies on the anti-osteoporosis activity of Baohuoside I. ( 31004988 )
2019
152
Investigation of transcriptome mechanism associated with osteoporosis explored by microarray analysis. ( 31007729 )
2019
153
A coordination project for improvement of osteoporosis medication use among patients who sustained osteoporotic fracture(s). ( 31008370 )
2019
154
Liuwei Dihuang Decoction for primary osteoporosis: A protocol for a systematic review and meta-analysis. ( 31008975 )
2019
155
Computational model of the dual action of PTH - Application to a rat model of osteoporosis. ( 31009612 )
2019
156
Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review. ( 31009947 )
2019
157
Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region. ( 31010789 )
2019
158
Long-term persistence in patients with osteoporosis receiving denosumab in routine practice: 36-month non-interventional, observational study. ( 31011760 )
2019
159
Osteocyte viability and bone density in cadmium chloride-induced osteoporosis ameliorated with Pilostigma thonningii stem bark-extracted D-3-O-methy-chiroinositol. ( 31016284 )
2019
160
Wnt3a involved in the mechanical loading on improvement of bone remodeling and angiogenesis in a postmenopausal osteoporosis mouse model. ( 31017804 )
2019
161
Correction: Screening for osteoporosis: A systematic assessment of the quality and content of clinical practice guidelines, using the AGREE II instrument and the IOM Standards for Trustworthy Guidelines. ( 31017978 )
2019
162
Screening and Treatment for Osteoporosis After Stroke. ( 31018778 )
2019
163
Transient osteoporosis of the hip after bariatric surgery. ( 31020018 )
2019
164
Diagnosis and Treatment of Osteoporosis: What Orthopaedic Surgeons Need to Know. ( 31021891 )
2019
165
Comparative efficacy and safety of pharmacological interventions for osteoporosis in postmenopausal women: a network meta-analysis (Chongqing, China). ( 31021904 )
2019
166
Differentially Expressed Circulating miRNAs in Postmenopausal Osteoporosis: A Meta-Analysis. ( 31023966 )
2019
167
Under-Recognition of Fractures as Osteoporosis Indicators. ( 31023977 )
2019
168
Impacts of Psychological Stress on Osteoporosis: Clinical Implications and Treatment Interactions. ( 31024360 )
2019
169
The age modification to leukocyte telomere length effect on bone mineral density and osteoporosis among Chinese elderly women. ( 31025211 )
2019
170
miR-363-3p is activated by MYB and regulates osteoporosis pathogenesis via PTEN/PI3K/AKT signaling pathway. ( 31025251 )
2019
171
Osteoporosis and Bone Health in Transgender Persons. ( 31027549 )
2019
172
Primary care physicians' views on osteoporosis management: a qualitative study. ( 31028556 )
2019
173
Agonist-induced activation of the S1P receptor 2 constitutes a novel osteoanabolic therapy for the treatment of osteoporosis in mice. ( 31028959 )
2019
174
Application of the recommendations of the Spanish Society of Rheumatology on osteoporosis in a Fracture Liaison Service unit. ( 31029566 )
2019
175
Additional procedures for measuring the effect of hysterectomy on osteoporosis. ( 31029666 )
2019
176
Chocolate and chocolate constituents influence bone health and osteoporosis risk. ( 31029926 )
2019
177
Effects of Rhizoma Drynariae Cataplasm on Fracture Healing in a Rat Model of Osteoporosis. ( 31030207 )
2019
178
Retrospective evaluation of persistence in osteoporosis therapy with oral bisphosphonates in Italy: the TOBI study. ( 31030419 )
2019
179
Disparities in osteoporosis by race/ethnicity, education, work status, immigrant status, and economic status in the United States. ( 31030967 )
2019
180
Observations on Osteoporosis in Three Generations of Descendants of Holocaust Survivors. ( 31032563 )
2019
181
Gendered perceptions of osteoporosis: implications for youth prevention programs. ( 31033426 )
2019
182
Association of menopausal symptoms as assessed from Greene Climacteric scale with body mass index and osteoporosis among rural women of North India. ( 31033995 )
2019
183
The Role of Macrophage in the Pathogenesis of Osteoporosis. ( 31035384 )
2019
184
Parity and lactation are not associated with incident fragility fractures or radiographic vertebral fractures over 16 years of follow-up: Canadian Multicentre Osteoporosis Study (CaMos). ( 31037359 )
2019
185
Determination of major components from Radix Achyranthes bidentate using ultra-performance liquid chromatography with triple quadrupole tandem mass spectrometry and an evaluation of their anti-osteoporosis effect in vitro. ( 31037819 )
2019
186
Men's experiences of having osteoporosis vertebral fractures: a qualitative study using interpretative phenomenological analyses. ( 31041474 )
2019
187
Efficacy and safety of elcatonin in postmenopausal women with osteoporosis: a systematic review with network meta-analysis of randomized clinical trials. ( 31041475 )
2019
188
Use of Hounsfield units of S1 body to diagnose osteoporosis in patients with lumbar degenerative diseases. ( 31042659 )
2019
189
Pediatric Osteoporosis. ( 31043448 )
2019
190
High FGF23 levels are associated with impaired trabecular bone microarchitecture in patients with osteoporosis. ( 31044263 )
2019
191
Bone Marrow Edema: A Case of Regional Migratory Osteoporosis. ( 31045875 )
2019
192
Artificial intelligence, osteoporosis and fragility fractures. ( 31045948 )
2019
193
Computer-aided osteoporosis detection from DXA imaging. ( 31046999 )
2019
194
Effect of Exercises on Quality of Life in Patients with Postmenopausal Osteoporosis - Randomized Trial. ( 31049100 )
2019
195
The Impact of Thyme and Rosemary on Prevention of Osteoporosis in Rats. ( 31049223 )
2019
196
The Status of Assessments and Treatments for Osteoporosis in Patients 5 Years after Total Hip Arthroplasty: A Cross-Sectional Survey of 194 Post-THA Patients. ( 31049227 )
2019
197
Sarcopenia and osteoporosis are interrelated in geriatric inpatients. ( 31049683 )
2019
198
Vitamin D Supplementation in France in Patients with or at Risk for Osteoporosis: Recent Data and New Practices. ( 31051244 )
2019
199
Abaloparatide improves cortical geometry and trabecular microarchitecture and increases vertebral and femoral neck strength in a rat model of male osteoporosis. ( 31051317 )
2019
200
The influence of Visfatin, RBP-4 and insulin resistance on bone mineral density in women with treated primary osteoporosis. ( 31054116 )
2019
201
Colony-stimulating factor 1 receptor inhibition prevents against lipopolysaccharide -induced osteoporosis by inhibiting osteoclast formation. ( 31054506 )
2019
202
Beta-blockers for osteoporosis: the sequel. ( 30784653 )
2019
203
Mmu-miR-185 depletion promotes osteogenic differentiation and suppresses bone loss in osteoporosis through the Bgn-mediated BMP/Smad pathway. ( 30787286 )
2019
204
IOF Regional 7th Asia-Pacific Osteoporosis Conference Sydney, Australia 2018-Posters Abstracts. ( 30788526 )
2019
205
Epigenetic regulation of BMP2 gene in osteoporosis: a DNA methylation study. ( 30788762 )
2019
206
The effect of robot-assisted surgery on lumbar pedicle screw internal fixation in patients with osteoporosis. ( 30790729 )
2019
207
Effects of 12-months treatment with zoledronate or teriparatide on intima-media thickness of carotid artery in women with postmenopausal osteoporosis: A pilot study. ( 30791743 )
2019
208
Correction to " In Vitro and in Vivo Evaluation of Osteoporosis Therapeutic Peptide PTH 1-34 Loaded PEGylated Chitosan Nanoparticles". ( 30793607 )
2019
209
Severe osteoporosis in a premenopausal woman. ( 30793635 )
2019
210
Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. ( 30796490 )
2019
211
Effect of caffeine on ovariectomy-induced osteoporosis in rats. ( 30797144 )
2019
212
Osteoporosis, bone mineral density and CKD-MBD (II): Therapeutic implications. ( 30797619 )
2019
213
Advancing Methods of Assessing Bone Quality to Expand Screening for Osteoporosis. ( 30801111 )
2019
214
Preventive Effects of Evodiamine on Dexamethasone-Induced Osteoporosis in Zebrafish. ( 30805367 )
2019
215
Correction to: Progression of frailty and prevalence of osteoporosis in a community cohort of older women-a 10-year longitudinal study. ( 30805677 )
2019
216
Extensive undertreatment of osteoporosis in older Swedish women. ( 30805678 )
2019
217
Cumambrin A prevents OVX-induced osteoporosis via the inhibition of osteoclastogenesis, bone resorption, and RANKL signaling pathways. ( 30807230 )
2019
218
Bioinformatics Analysis Reveals the Altered Gene Expression of Patients with Postmenopausal Osteoporosis Using Liuweidihuang Pills Treatment. ( 30809532 )
2019
219
Efficacy and safety of Zuogui Pill in treating osteoporosis: Study protocol of a systematic review. ( 30813123 )
2019
220
Combating osteoporosis and obesity with exercise: leveraging cell mechanosensitivity. ( 30814687 )
2019
221
Tiliroside is a new potential therapeutic drug for osteoporosis in mice. ( 30815860 )
2019
222
Maximal dose-response of vitamin-K2 (menaquinone-4) on undercarboxylated osteocalcin in women with osteoporosis. ( 30816822 )
2019
223
Higher rates of osteoporosis treatment initiation and persistence in patients with newly diagnosed vertebral fracture when introduced in inpatients than later in outpatients. ( 30820609 )
2019
224
Osteoporosis Medication Use: A Comparison of Elderly Females Living in Long-term Care Facilities Versus Community Dwellers. ( 30821669 )
2019
225
The Correlation between Osteoporosis and Blood Circulation Function Based on Magnetic Resonance Imaging. ( 30826890 )
2019
226
Osteoporosis and hearing loss: findings from the Korea National Health and Nutrition Examination Survey 2009-2011. ( 30827872 )
2019
227
Opportunistic osteoporosis screening in multi-detector CT images via local classification of textures. ( 30830261 )
2019
228
Challenges in osteoporosis awareness and management: results from a survey of US postmenopausal women. ( 30834163 )
2019
229
Effects of Acupoint Application Therapy with TianGui Powder on Osteoporosis in Ovariectomized Rats through TGF-β1 and Smad2/3 Signaling Pathway. ( 30834706 )
2019
230
Protective Effects of Ligustroflavone, an Active Compound from Ligustrum lucidum, on Diabetes-Induced Osteoporosis in Mice: A Potential Candidate as Calcium-Sensing Receptor Antagonist. ( 30834778 )
2019
231
Lipid profiles as potential mediators linking body mass index to osteoporosis among Chinese adults: the Henan Rural Cohort Study. ( 30834945 )
2019
232
Wnt Antagonists in Hematopoietic and Immune Cell Fate: Implications for Osteoporosis Therapies. ( 30835038 )
2019
233
The burden of osteoporosis in four Latin American countries: Brazil, Mexico, Colombia, and Argentina. ( 30835577 )
2019
234
Reduction in body cell mass as a predictor of osteoporosis: A cross-sectional study. ( 30836039 )
2019
235
Membrane trafficking in osteoclasts and implications for osteoporosis. ( 30837319 )
2019
236
Increased risk of benign paroxysmal positional vertigo in osteoporosis: a nationwide population-based cohort study. ( 30837524 )
2019
237
Bone-Specific Overexpression of PITX1 Induces Senile Osteoporosis in Mice Through Deficient Self-Renewal of Mesenchymal Progenitors and Wnt Pathway Inhibition. ( 30837642 )
2019
238
Profile of Women Initiated on Denosumab and Pattern of Use in a Restricted Postmenopausal Osteoporosis Indication: A French Database Analysis Over the Period 2013-2014. ( 30838517 )
2019
239
Osteoporosis awareness and health beliefs among Lebanese women aged 40 years and above. ( 30840113 )
2019
240
Orthopedic surgeons' views on the osteoporosis care gap and potential solutions: survey results. ( 30841897 )
2019
241
The effect of alcohol on osteoporosis: A systematic review and meta-analysis. ( 30844616 )
2019
242
Interleukin-33 serum levels in postmenopausal women with osteoporosis. ( 30846811 )
2019
243
The epidemiology of osteoporosis, associated fragility fractures, and management gap in China. ( 30848398 )
2019
244
Wrist Fractures and Osteoporosis. ( 30850079 )
2019
245
Surgical Considerations in Managing Osteoporosis, Osteopenia, and Vitamin D Deficiency During Arthroscopic Rotator Cuff Repair. ( 30850081 )
2019
246
Surgical Considerations for Osteoporosis in Ankle Fracture Fixation. ( 30850082 )
2019
247
Surgical Considerations for Osteoporosis, Osteopenia, and Vitamin D Deficiency. ( 30850084 )
2019
248
Revised FRAX®-based intervention thresholds for the management of osteoporosis among postmenopausal women in Sri Lanka. ( 30850909 )
2019
249
Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review. ( 30854568 )
2019
250
Efficacy of Jintiange Capsules in the Treatment of Osteoporosis: A Network Meta-analysis. ( 30854796 )
2019
251
Correlation of rs749292 and rs700518 polymorphisms in the aromatase gene (CYP19A1) with osteoporosis in postmenopausal Polish women. ( 30855728 )
2019
252
Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis. ( 30856013 )
2019
253
New Insights Into Monogenic Causes of Osteoporosis. ( 30858824 )
2019
254
Evidence of patient beliefs, values, and preferences is not provided in osteoporosis clinical practice guidelines. ( 30859238 )
2019
255
Vitamin C reverses bone loss in an osteopenic rat model of osteoporosis. ( 30859904 )
2019
256
High-Intensity Resistance and Impact Training Improves Bone Mineral Density and Physical Function in Postmenopausal Women With Osteopenia and Osteoporosis: The LIFTMOR Randomized Controlled Trial. ( 30861219 )
2019
257
Drugs targeting SIRT1, a new generation of therapeutics for osteoporosis and other bone related disorders? ( 30862606 )
2019
258
A join point regression analysis of trends in mortality due to osteoporosis in Spain. ( 30862942 )
2019
259
Gut Hormones and Their Effect on Bone Metabolism. Potential Drug Therapies in Future Osteoporosis Treatment. ( 30863364 )
2019
260
TRANSIENT OSTEOPOROSIS: CLINICAL SPECTRUM IN ADULTS AND ASSOCIATED RISK FACTORS. ( 30865521 )
2019
261
Correction: Identification of 613 new loci associated with heel bone mineral density and a polygenic risk score for bone mineral density, osteoporosis and fracture. ( 30865700 )
2019
262
Prediction of pivotal pathways and hub genes associated with osteoporosis by Gibbs sampling. ( 30867698 )
2019
263
Stages of sarcopenia, bone mineral density, and the prevalence of osteoporosis in older women. ( 30868338 )
2019
264
Bone Metabolism Markers in Thalassemia Major-Induced Osteoporosis: Results from a Cross-Sectional Observational Study. ( 30868952 )
2019
265
Clinical Update on Osteoporosis. ( 30869832 )
2019
266
Methoxsalen and Bergapten Prevent Diabetes-Induced Osteoporosis by the Suppression of Osteoclastogenic Gene Expression in Mice. ( 30875838 )
2019
267
The 2018 Guidelines for the diagnosis and treatment of osteoporosis in Greece. ( 30877479 )
2019
268
Functional characterization of the C7ORF76 genomic region, a prominent GWAS signal for osteoporosis in 7q21.3. ( 30878523 )
2019
269
Treating osteoporosis: a near miss in an unusual case of FGF-23 mediated bone loss. ( 30878966 )
2019
270
An Evaluation of the Association of Reproductive History and Multiple Births during Adolescence with Postmenopausal Osteoporosis. ( 30880829 )
2019
271
Relationship between abnormal glucose metabolism and osteoporosis in Han Chinese men over the age of 50 years. ( 30880926 )
2019
272
Efficacy of denosumab therapy for a 21-year-old woman with Prader-Willi syndrome, osteoporosis and history of fractures: a case report. ( 30880995 )
2019
273
Monthly Intramuscular Neridronate for the Treatment of Postmenopausal Osteoporosis: Results of a 6-Year Prospective Italian Study. ( 30881452 )
2019
274
Mandibular Trabecular Bone Analysis Using Local Binary Pattern for Osteoporosis Diagnosis. ( 30881937 )
2019
275
There is an association between sarcopenia, osteoporosis, and the risk of hip fracture. ( 30885101 )
2019
276
A new biosensor for osteoporosis detection. ( 30888246 )
2019
277
Predicting osteoporosis medication receipt in Veterans with a spinal cord injury: A retrospective cohort study. ( 30888309 )
2019
278
Osteoporosis and the Ageing Skeleton. ( 30888662 )
2019
279
The Role of Tocotrienol in Preventing Male Osteoporosis-A Review of Current Evidence. ( 30889819 )
2019
280
Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: A meta-analysis. ( 30890377 )
2019
281
Efficacy of weight adjusted bone mineral content in osteoporosis diagnosis in Chinese female population. ( 30897592 )
2019
282
Clinical Application of Bone Turnover Markers in Osteoporosis in Korea. ( 30899720 )
2019
283
IOF Regional 7th Asia-Pacific Osteoporosis Conference Sydney, Australia 2018 - Author Index. ( 30899993 )
2019
284
Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis. ( 30899994 )
2019
285
Osteoporosis therapies might lead to intervertebral disc degeneration via affecting cartilage endplate. ( 30902151 )
2019
286
Identification of hub genes associated with postmenopausal osteoporosis by Gibbs sampling method. ( 30906457 )
2019
287
Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. ( 30907953 )
2019
288
Women's Values and Preferences Regarding Osteoporosis Treatments: A Systematic Review. ( 30907968 )
2019
289
Consumption of milk and dairy products and risk of osteoporosis and hip fracture: a systematic review and Meta-analysis. ( 30909722 )
2019
290
Hypercalcemia and acute kidney injury induced by eldecalcitol in patients with osteoporosis: a case series of 32 patients at a single facility. ( 30909788 )
2019
291
Patient Perceptions and Preferences for Osteoporosis Treatment. ( 30910239 )
2019
292
Black Rice (Oryza sativa L.) Fermented with Lactobacillus casei Attenuates Osteoclastogenesis and Ovariectomy-Induced Osteoporosis. ( 30911544 )
2019
293
Is Trabecular Bone Score a More Sensitive Marker for Osteoporosis in Asthmatics? ( 30912320 )
2019
294
Opportunistic Osteoporosis Screening at Routine Abdominal and Thoracic CT: Normative L1 Trabecular Attenuation Values in More than 20 000 Adults. ( 30912719 )
2019
295
Independent Roles of Estrogen Deficiency and Cellular Senescence in the Pathogenesis of Osteoporosis: Evidence in Young Adult Mice and Older Humans. ( 30913313 )
2019
296
Linkage of microbiota and osteoporosis: A mini literature review. ( 30918795 )
2019
297
Humulus lupulus L. Extract Prevents Ovariectomy-Induced Osteoporosis in Mice and Regulates Activities of Osteoblasts and Osteoclasts. ( 30919241 )
2019
298
Improving the accuracy of medication adherence measures using linked prescription and dispensation data: findings from the ESOSVAL cohort of patients treated with osteoporosis drugs. ( 30924690 )
2019
299
Tai chi for treating osteopenia and primary osteoporosis: a meta-analysis and trial sequential analysis. ( 30655662 )
2019
300
Identification of core genes and prediction of miRNAs associated with osteoporosis using a bioinformatics approach. ( 30655789 )
2019
301
Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis. ( 30656367 )
2019
302
Treating osteoporosis to prevent fractures: current concepts and future developments. ( 30657216 )
2019
303
Down-regulation of miR-339 promotes differentiation of BMSCs and alleviates osteoporosis by targeting DLX5. ( 30657543 )
2019
304
Let-7a-5p inhibits BMSCs osteogenesis in postmenopausal osteoporosis mice. ( 30660362 )
2019
305
LncRNA ZBTB40-IT1 modulated by osteoporosis GWAS risk SNPs suppresses osteogenesis. ( 30661131 )
2019
306
Pyrroloquinoline Quinone Prevents Estrogen Deficiency-Induced Osteoporosis by Inhibiting Oxidative Stress and Osteocyte Senescence. ( 30662347 )
2019
307
Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis. ( 30663085 )
2019
308
Multiple severe vertebral fractures during the 3-month period following a missed dose of denosumab in a postmenopausal woman with osteoporosis previously treated with alendronate
. ( 30663978 )
2019
309
Denosumab effects on serum levels of the bone morphogenetic proteins antagonist noggin in patients with transfusion-dependent thalassemia and osteoporosis. ( 30665323 )
2019
310
Interleukin-6 Inhibitor Suppresses Hyperalgesia Without Improvement in Osteoporosis in a Mouse Pain Model of Osteoporosis. ( 30666355 )
2019
311
IOF Regional 7th Asia-Pacific Osteoporosis Conference Sydney, Australia 2018 - IOF-APOA Joint Session Abstracts. ( 30666371 )
2019
312
Bone-targeting drug delivery system of biomineral-binding liposomes loaded with icariin enhances the treatment for osteoporosis. ( 30670021 )
2019
313
Can increasing the prevalence of vegetable-based diets lower the risk of osteoporosis in postmenopausal subjects? A systematic review with meta-analysis of the literature. ( 30670259 )
2019
314
Pregnancy-associated osteoporosis: a UK case series and literature review. ( 30671611 )
2019
315
Hub genes and gene functions associated with postmenopausal osteoporosis predicted by an integrated method. ( 30680001 )
2019
316
The Costs of Confronting Osteoporosis: Cost Study of an Australian Fracture Liaison Service. ( 30680364 )
2019
317
IOF Regional 7th Asia-Pacific Osteoporosis Conference Sydney, Australia 2018 - Meet-the-Expert Sessions Abstracts. ( 30688992 )
2019
318
IOF Regional 7th Asia-Pacific Osteoporosis Conference Sydney, Australia 2018 - Plenary Lecture Abstracts. ( 30688993 )
2019
319
IOF Regional 7th Asia-Pacific Osteoporosis Conference Sydney, Australia 2018 - Opening ceremony Abstracts. ( 30688994 )
2019
320
IOF Regional 7th Asia-Pacific Osteoporosis Conference Sydney, Australia 2018 - Sponsored Symposia Abstracts. ( 30688995 )
2019
321
IOF Regional 7th Asia-Pacific Osteoporosis Conference Sydney, Australia - 2018 - IOF-OA-ANZBMS Joint Session Abstracts. ( 30688996 )
2019
322
Abaloparatide: A new pharmacological option for osteoporosis. ( 30689744 )
2019
323
Wnt signaling pathway in osteoporosis: Epigenetic regulation, interaction with other signaling pathways, and therapeutic promises. ( 30693508 )
2019
324
Osteoporosis. ( 30696576 )
2019
325
Treatment with once-weekly alendronate oral jelly compared with once-weekly alendronate oral tablet for Japanese patients with primary osteoporosis: An open-label, prospective, observational study. ( 30697599 )
2019
326
IOF Regional 7th Asia-Pacific Osteoporosis Conference Sydney, Australia 2018 - Committee of National Societies (CNS) Roundtable Abstracts. ( 30701341 )
2019
327
Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France. ( 30701342 )
2019
328
Sex differences in osteoporosis self-efficacy among community-residing older adults presenting for DXA. ( 30701343 )
2019
329
Update on Osteoporosis. ( 30704657 )
2019
330
Vertebral augmentation in osteoporosis: common procedures for spinal fractures show no benefit. ( 30705023 )
2019
331
Clinical decision support system for the management of osteoporosis compared to NOGG guidelines and an osteology specialist: a validation pilot study. ( 30709348 )
2019
332
A potential therapeutic target for regulating osteoporosis via suppression of osteoclast differentiation. ( 30716449 )
2019
333
Decreased fracture incidence with traditional Chinese medicine therapy in patients with osteoporosis: a nationwide population-based cohort study. ( 30717733 )
2019
334
MicroRNA-9-5p promotes osteoporosis development through inhibiting osteogenesis and promoting adipogenesis via targeting Wnt3a. ( 30720151 )
2019
335
Association of use of Chinese herbal medicines and the risk of fracture in patients with osteoporosis: a population-based cohort study. ( 30721331 )
2019
336
Dehydrocostus lactone (DHC) suppresses estrogen deficiency-induced osteoporosis. ( 30721671 )
2019
337
Suboptimal osteoporosis evaluation and treatment in older men with and without additional high-risk factors for fractures. ( 30723121 )
2019
338
Incident Fragility Fractures Have a Long-Term Negative Impact on Health-Related Quality of Life of Older People: The Canadian Multicentre Osteoporosis Study. ( 30723960 )
2019
339
Should clinicians pay more attention to the potential underdiagnosis of osteoporosis in patients with ankylosing spondylitis? A national population-based study in Taiwan. ( 30726282 )
2019
340
Biomarkers of Osteoporosis: An Update. ( 30727928 )
2019
341
Cost-Effectiveness of Pharmacological Treatments for Osteoporosis Consistent with the Revised Economic Evaluation Guidelines for Canada. ( 30729168 )
2019
342
Controlled Delivery of Salmon Calcitonin Using Thermosensitive Triblock Copolymer Depot for Treatment of Osteoporosis. ( 30729223 )
2019
343
A path analysis model suggesting the association of information and beliefs with self-efficacy in osteoporosis prevention among middle-aged and older community residents in urban Shanghai, China. ( 30730963 )
2019
344
A prospective comparative study of intravenous alendronate and ibandronate for the treatment of osteoporosis. ( 30732159 )
2019
345
Prevalence of osteoporosis and osteopenia in men and premenopausal women with celiac disease: a systematic review. ( 30732599 )
2019
346
A fructooligosaccharide from Achyranthes bidentata inhibits osteoporosis by stimulating bone formation. ( 30732743 )
2019
347
Prophylactic vertebroplasty versus kyphoplasty in osteoporosis: A comprehensive biomechanical matched-pair study by in vitro compressive testing. ( 30733174 )
2019
348
The efficacy and safety of menatetrenone in the management of osteoporosis: a systematic review and meta-analysis of randomized controlled trials. ( 30734066 )
2019
349
Risk of osteoporosis and fracture in victims with burn injury. ( 30734067 )
2019
350
Osteoporosis is inversely associated with arterial stiffness in the elderly: An investigation using the Osteoporosis Self-assessment Tool for Asians index in an elderly Chinese cohort. ( 30734463 )
2019
351
Effects of Eclipta prostrata on gut microbiota of SAMP6 mice with osteoporosis. ( 30735116 )
2019
352
Understanding and managing secondary osteoporosis. ( 30735441 )
2019
353
Protective effects of Dipsacus asper polysaccharide on osteoporosis in vivo by regulating RANKL/RANK/OPG/VEGF and PI3K/Akt/eNOS pathway. ( 30735778 )
2019
354
SAA1 gene polymorphisms in osteoporosis patients. ( 30737305 )
2019
355
IOF Regional 7th Asia-Pacific Osteoporosis Conference Sydney, Australia 2018 - Oral Communications Abstracts. ( 30737576 )
2019
356
A case-control study of the association between sialolithiasis and osteoporosis. ( 30740891 )
2019
357
Cav1.3 is upregulated in osteoporosis rat model and promotes osteoclast differentiation from preosteoclast cell line RAW264.7. ( 30741411 )
2019
358
Hyponatremia Is Associated With Increased Osteoporosis and Bone Fractures in Patients With Diabetes With Matched Glycemic Control. ( 30746503 )
2019
359
Race Plays a Role in the Knowledge, Attitudes, and Beliefs of Women with Osteoporosis. ( 30747331 )
2019
360
Raman spectroscopy as a predictive tool for monitoring osteoporosis therapy in a rat model of postmenopausal osteoporosis. ( 30747334 )
2019
361
Invasive Oral Procedures and Events in Women With Postmenopausal Osteoporosis Treated With Denosumab for up to 10 Years. ( 30759221 )
2019
362
Quantitative diagnosis of osteoporosis using lumbar spine signal intensity in magnetic resonance imaging. ( 30759992 )
2019
363
Zebrafish as an Emerging Model for Osteoporosis: A Primary Testing Platform for Screening New Osteo-Active Compounds. ( 30761080 )
2019
364
Osteoporosis strategic plan for the Middle East and North Africa region. ( 30761432 )
2019
365
Abaloparatide (Tymlos) for Osteoporosis. ( 30763045 )
2019
366
Cemented versus uncemented femoral component total hip arthroplasty in elderly patients with primary osteoporosis: retrospective analysis with 5-year follow-up. ( 30764684 )
2019
367
Increased the risk of osteoporosis with hysterectomy: A longitudinal follow-up study using a national sample cohort. ( 30768935 )
2019
368
Discrimination of osteoporosis-related vertebral fractures by DXA-derived 3D measurements: a retrospective case-control study. ( 30770938 )
2019
369
Deregulated miRNAs in bone health: Epigenetic roles in osteoporosis. ( 30772601 )
2019
370
Utility of the Serum Cystatin C Level for Diagnosis of Osteoporosis among Middle-Aged and Elderly People. ( 30775381 )
2019
371
Osteoporosis and prostate cancer; a 24-month prospective observational study during androgen deprivation therapy. ( 30777478 )
2019
372
Discovery of potential biomarkers for osteoporosis using LC-MS/MS metabolomic methods. ( 30778642 )
2019
373
Comparison of radiological and functional outcome of unstable intertrochanteric femur fractures treated using PFN and PFNA-2 in patients with osteoporosis. ( 30778679 )
2019
374
Circ-VANGL1 promotes the progression of osteoporosis by absorbing miRNA-217 to regulate RUNX2 expression. ( 30779060 )
2019
375
Bone marrow stem cells derived exosomes improve osteoporosis by promoting osteoblast proliferation and inhibiting cell apoptosis. ( 30779091 )
2019
376
Shared mechanisms: osteoporosis and Alzheimer's disease? ( 30779704 )
2019
377
Osteoporosis and skeletal dysplasia caused by pathogenic variants in SGMS2. ( 30779713 )
2019
378
Treated Osteoporosis Is Still Osteoporosis. ( 30779859 )
2019
379
Cost-effectiveness of osteoporosis screening using biomechanical computed tomography for patients with a previous abdominal CT. ( 30779860 )
2019
380
Cost-effectiveness of Osteoporosis Interventions to Improve Quality of Care after Upper Extremity Fracture: Results from a Randomized Trial (C-STOP Trial). ( 30779861 )
2019
381
Microsimulation model for the health economic evaluation of osteoporosis interventions: study protocol. ( 30782956 )
2019
382
Osteoporosis and the Critically Ill Patient. ( 30784611 )
2019
383
Exercise for the prevention of osteoporosis in postmenopausal women: an evidence-based guide to the optimal prescription. ( 30503353 )
2019
384
Assessing the effects of long-term osteoporosis treatment by using conventional spine radiographs: results from a pilot study in a sub-cohort of a large randomized controlled trial. ( 30506302 )
2019
385
Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study. ( 30535785 )
2019
386
A Comparison of US and Canadian Osteoporosis Screening and Treatment Strategies in Postmenopausal Women. ( 30536628 )
2019
387
Combination therapy with parathyroid hormone analogs and antiresorptive agents for osteoporosis: a systematic review and meta-analysis of randomized controlled trials. ( 30539271 )
2019
388
Retraction: Paper "Combined Treatment with Vitamin K₂ and Bisphosphonate in Postmenopausal Women with Osteoporosis" by Iwamoto J, et al. [Yonsei Med J 2003;44(5):751-756]. ( 30554498 )
2019
389
Retraction: Paper "Comparison of Effect of Treatment with Etidronate and Alendronate on Lumbar Bone Mineral Density in Elderly Women with Osteoporosis" by Iwamoto J, et al. [Yonsei Med J 2005;46(6):750-758]. ( 30554500 )
2019
390
New therapeutic targets for osteoporosis. ( 30583758 )
2019
391
Osteogenic effects of Phlomis umbrosa via up-regulation of Runx2 in osteoporosis. ( 30588298 )
2019
392
An atlas of genetic influences on osteoporosis in humans and mice. ( 30598549 )
2019
393
Osteoporosis and sport. ( 30599856 )
2019
394
Association of RMND1/CCDC170-ESR1 single nucleotide polymorphisms with hip fracture and osteoporosis in postmenopausal women. ( 30601066 )
2019
395
Higher Dairy Intakes Are Associated with Higher Bone Mineral Density among Adults with Sufficient Vitamin D Status: Results from the Boston Puerto Rican Osteoporosis Study. ( 30601986 )
2019
396
Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis. ( 30603840 )
2019
397
Pulsed electromagnetic fields: promising treatment for osteoporosis. ( 30603841 )
2019
398
Rapamycin improves bone mass in high-turnover osteoporosis with iron accumulation through positive effects on osteogenesis and angiogenesis. ( 30610968 )
2019
399
WY 1048, a 17-methyl 19-nor D-ring analog of vitamin D3, in combination with risedronate restores bone mass in a mouse model of postmenopausal osteoporosis. ( 30611910 )
2019
400
Executive summary of European guidance for the diagnosis and management of osteoporosis in postmenopausal women. ( 30612282 )
2019
401
Low knowledge of osteoporosis and its risk factors in urban Indian adults from Pune city, India. ( 30612590 )
2019
402
Clinical utility of bone turnover markers in monitoring the withdrawal of treatment with oral bisphosphonates in postmenopausal osteoporosis. ( 30613868 )
2019
403
Spontaneous Vertebral Fractures in Males with Osteoporosis After Denosumab Discontinuation: A Report of Two Cases. ( 30614889 )
2019
404
The Cost of Osteoporosis, Osteopenia, and Associated Fractures in Australia in 2017. ( 30615801 )
2019
405
Are we closing the gaps in the management of osteoporosis following fragility fractures of the femur? ( 30616478 )
2019
406
Activated vitamin D3 formulations can be safely used as concomitant medication for prevention of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis. ( 30618176 )
2019
407
Bone mineral density and osteoporosis in heart transplanted patients: A single-centre retrospective study at Skåne University Hospital in Lund 1988-2016. ( 30618200 )
2019
408
Hyperglycemic status is associated with an elevated risk of osteoporotic fracture in community-dwelling elderly Japanese men: The Fujiwara-kyo osteoporosis risk in men (FORMEN) cohort study. ( 30620891 )
2019
409
Effect of treatment on back pain and back extensor strength with a spinal orthosis in older women with osteoporosis: a randomized controlled trial. ( 30623268 )
2019
410
Assessment and hormonal management of osteoporosis. ( 30624083 )
2019
411
Association of VDR and OPG gene polymorphism with osteoporosis risk in Chinese postmenopausal women. ( 30624097 )
2019
412
Application of ICF conceptual framework in Osteoporosis. ( 30628503 )
2019
413
Bone mineral density as a dose-response predictor for osteoporosis: a propensity score analysis of longitudinal incident study (KCIS no. 39). ( 30629251 )
2019
414
Parkinson's Disease as Risk Factor in Osteoporosis and Osteoporotic Vertebral Fracture : Prevalence Study Using National Inpatient Sample Database in Korea. ( 30630295 )
2019
415
Common mechanisms and holistic care in atherosclerosis and osteoporosis. ( 30630495 )
2019
416
Preventing and Treating Osteoporosis. ( 30635461 )
2019
417
Chronic hyponatremia and association with osteoporosis among a large racially/ethnically diverse population. ( 30635697 )
2019
418
A dual-label time-resolved fluorescence immunoassay for screening of osteoporosis based on simultaneous detection of C-terminal telopeptide (β-CTX) and aminoterminal propeptide (P1NP) of type I procollagen. ( 30638079 )
2019
419
The effects of dual-task balance training on gait in older women with osteoporosis: A randomized controlled trial. ( 30640156 )
2019
420
Osteoporosis knowledge and awareness among university students in Saudi Arabia. ( 30644020 )
2019
421
Unravelling the genetics of osteoporosis. ( 30647468 )
2019
422
Urinary N-telopeptide: The New Diagnostic Test for Osteoporosis. ( 30648159 )
2019
423
Oviductus Ranae protein hydrolyzate prevents menopausal osteoporosis by regulating TGFβ/BMP2 signaling. ( 30649603 )
2019
424
Long non-coding RNA XIST promotes osteoporosis through inhibiting bone marrow mesenchymal stem cell differentiation. ( 30651866 )
2019
425
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. ( 30324412 )
2019
426
Madecassoside inhibits estrogen deficiency-induced osteoporosis by suppressing RANKL-induced osteoclastogenesis. ( 30338925 )
2019
427
Prescreening for Osteoporosis With Quantitative Ultrasound in Postmenopausal White Women. ( 30341956 )
2019
428
The first biosimilar approved for the treatment of osteoporosis: results of a comparative pharmacokinetic/pharmacodynamic study. ( 30357438 )
2019
429
Proceedings of the 2018 Santa Fe Bone Symposium: Advances in the Management of Osteoporosis. ( 30366683 )
2019
430
COMMENTARY ON MANAGEMENT OF OSTEOPOROSIS IN ADVANCED CKD: COMMON VIEW OF A NEPHROLOGIST AND A BONE SPECIALIST. ( 30383488 )
2019
431
Knockdown of TRPV4 suppresses osteoclast differentiation and osteoporosis by inhibiting autophagy through Ca2+ -calcineurin-NFATc1 pathway. ( 30387123 )
2019
432
Review of the Literature Examining the Association of Serum Uric Acid with Osteoporosis and Mechanistic Insights into Its Effect on Bone Metabolism. ( 30387405 )
2019
433
Prediction of Abnormal Bone Density and Osteoporosis From Lumbar Spine MR Using Modified Dixon Quant in 257 Subjects With Quantitative Computed Tomography as Reference. ( 30390360 )
2019
434
Screening for natural medicines effective for the treatment of osteoporosis. ( 30392168 )
2019
435
Muscle mass measures and incident osteoporosis in a large cohort of postmenopausal women. ( 30398016 )
2019
436
Hormone therapy and osteoporosis in breast cancer survivors: assessment of risk and adherence to screening recommendations. ( 30413856 )
2019
437
Evolving Role of MR Imaging and PET in Assessing Osteoporosis. ( 30420220 )
2019
438
Population-based opportunistic osteoporosis screening: Validation of a fully automated CT tool for assessing longitudinal BMD changes. ( 30433815 )
2019
439
Combining information from multiple bone turnover markers as diagnostic indices for osteoporosis using support vector machines. ( 30442069 )
2019
440
MANAGEMENT OF ENDOCRINE DISEASE: Treatment breaks in long-term management of osteoporosis. ( 30444721 )
2019
441
Consensus statement on the use of HRT in postmenopausal women in the management of osteoporosis by SIE, SIOMMMS and SIGO. ( 30456623 )
2019
442
Effect of Primary Hypertension on Treatment Outcomes of Patients with Postmenopausal Osteoporosis: A 5 Year Follow Up Retrospective Study. ( 30467637 )
2019
443
Dissecting the Genetics of Osteoporosis using Systems Approaches. ( 30470485 )
2019
444
Study description and baseline characteristics of the population enrolled in a multinational, observational study of teriparatide in postmenopausal women with osteoporosis: the Asia and Latin America Fracture Observational Study (ALAFOS). ( 30474449 )
2019
445
Improvement of region of interest extraction and scanning method of computer-aided diagnosis system for osteoporosis using panoramic radiographs. ( 30484188 )
2019
446
Prospect of mesenchymal stem cells in therapy of osteoporosis: A review. ( 30488448 )
2019
447
Reduced TIPE2 expression is inversely associated with proinflammatory cytokines and positively correlated with bone mineral density in patients with osteoporosis. ( 30496728 )
2019
448
Osteoporosis-pseudoglioma syndrome: clinical, genetic, and treatment-response study of 10 new cases in Greece. ( 30499050 )
2019
449
Low bone mineral density is associated with an elevated risk of developing increased arterial stiffness: A 10-year follow-up of Japanese women from the Japanese Population-based Osteoporosis (JPOS) cohort study. ( 30502749 )
2019
450
Cajaninstilbene acid inhibits osteoporosis through suppressing osteoclast formation and RANKL-induced signaling pathways. ( 30515822 )
2019
451
NADPH oxidases in bone homeostasis and osteoporosis. ( 30189265 )
2019
452
Irp2 Knockout Causes Osteoporosis by Inhibition of Bone Remodeling. ( 30191282 )
2019
453
Effect of autophagy gene DRAM on proliferation, cell cycle, apoptosis, and autophagy of osteoblast in osteoporosis rats. ( 30203495 )
2019
454
A Prospective, Controlled, Multicenter Study to Evaluate the Clinical Outcome of Implant Treatment in Women with Osteoporosis/Osteopenia: 5-Year Results. ( 30205020 )
2019
455
Vitamin D and Bone Mineral Density in HIV Newly Diagnosed Therapy-Naive Patients Without Any Secondary Causes of Osteoporosis. ( 30209528 )
2019
456
OFELIA: Prevalence of Osteoporosis in Fragility Fracture Patients. ( 30225727 )
2019
457
Linking of psoriasis with osteopenia and osteoporosis: A cross-sectional study. ( 30226478 )
2019
458
Adherence to osteoporosis therapy after an upper extremity fracture: a pre-specified substudy of the C-STOP randomized controlled trial. ( 30232538 )
2019
459
Assessment of patient-reported outcomes (PROs): treatment satisfaction, medication adherence, and quality of life (QoL) and the associated factors in postmenopausal osteoporosis (PMO) patients in Korea. ( 30238428 )
2019
460
Artificial Intelligence Applied to Osteoporosis: A Performance Comparison of Machine Learning Algorithms in Predicting Fragility Fractures From MRI Data. ( 30252971 )
2019
461
Comparison of the diagnostic performance of CT Hounsfield unit histogram analysis and dual-energy X-ray absorptiometry in predicting osteoporosis of the femur. ( 30255256 )
2019
462
French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation. ( 30287350 )
2019
463
Osteoporosis prevention: where are the barriers to improvement in a French general population? A qualitative study. ( 30306220 )
2019
464
Hepatocyte growth factor is a potential biomarker for osteoproliferation and osteoporosis in ankylosing spondylitis. ( 30306221 )
2019
465
Night shift work and osteoporosis: evidence and hypothesis. ( 30311808 )
2019
466
Structural elucidation and anti-osteoporosis activities of polysaccharides obtained from Curculigo orchioides. ( 30318216 )
2019
467
Study design of multi-center, open-label randomized controlled, head-to-head trial comparing minodronic acid and raloxifene: Japanese Osteoporosis Intervention Trial (JOINT)-04. ( 30019249 )
2019
468
Does Combined Osteopenia/Osteoporosis and Sarcopenia Confer Greater Risk of Falls and Fracture Than Either Condition Alone in Older Men? The Concord Health and Ageing in Men Project. ( 30032209 )
2019
469
Treatment of osteoporosis with recombinant parathyroid hormone, utilisation of total body DXA to observe treatment effects on total body composition and factors determining response to therapy. ( 30032480 )
2019
470
Idiopathic benign paroxysmal positional vertigo with persistent vertigo/dizziness sensation is associated with latent canal paresis, endolymphatic hydrops, and osteoporosis. ( 30042018 )
2019
471
Impact of the implementation of a Fracture Liaison Service on pharmaceutical expenses for osteoporosis compared to an area without an FLS. ( 30129375 )
2019
472
Synergistic effects of combined therapy of curcumin and Fructus Ligustri Lucidi for treatment of osteoporosis: cellular and molecular evidence of enhanced bone formation. ( 30139656 )
2019
473
Rates of osteoporosis screening and treatment following vertebral fracture. ( 30142455 )
2019
474
The impact of switching once-weekly teriparatide to denosumab in osteoporosis patients. ( 30146385 )
2019
475
Dielectric properties of bones for the monitoring of osteoporosis. ( 30159660 )
2019
476
Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States. ( 30160186 )
2019
477
Reasonable adjustments to provide equitable and inclusive assessment, screening and treatment of osteoporosis for adults with intellectual disabilities: A feasibility study. ( 30175427 )
2019
478
Emerging Technologies in Osteoporosis Diagnosis. ( 30177358 )
2019
479
Radiofrequency echographic multispectrometry compared with dual X-ray absorptiometry for osteoporosis diagnosis on lumbar spine and femoral neck. ( 30178159 )
2019
480
The association between cumulative cadmium intake and osteoporosis and risk of fracture in a Chinese population. ( 30185939 )
2019
481
Autophagy: A Promising Target for Age-related Osteoporosis. ( 29943700 )
2019
482
Guidelines for the management of osteoporosis and fragility fractures. ( 29948835 )
2019
483
A randomized, double-blind, placebo-controlled study of once weekly elcatonin in primary postmenopausal osteoporosis. ( 29986611 )
2019
484
Current and Emerging Diagnostic Imaging-Based Techniques for Assessment of Osteoporosis and Fracture Risk. ( 29994405 )
2019
485
Relationship between carotid or coronary artery calcification and osteoporosis in the elderly. ( 29696936 )
2019
486
Factors associated with inadequate responses to risedronate in Japanese patients with osteoporosis. ( 29737412 )
2019
487
Evaluation of ostarine as a selective androgen receptor modulator in a rat model of postmenopausal osteoporosis. ( 29785666 )
2019
488
Gender differences in anti-osteoporosis drug treatment after osteoporotic fractures. ( 29536198 )
2019
489
Inter-rater reliability of DartfishTM movement analysis software for measuring maximum flexion and extension at the hip and knee in older adults with osteoporosis and osteopenia. ( 29589776 )
2019
490
Development of PEI-RANK siRNA Complex Loaded PLGA Nanocapsules for the Treatment of Osteoporosis. ( 29652606 )
2019
491
Failure in diagnosis and under-treatment of osteoporosis in elderly patients with fragility fractures. ( 29667007 )
2019
492
The increase in bone mineral density by bisphosphonate with active vitamin D analog is associated with the serum calcium level within the reference interval in postmenopausal osteoporosis. ( 29451049 )
2019
493
Association of cystatin C- and creatinine-based eGFR with osteoporotic fracture in Japanese postmenopausal women with osteoporosis: sarcopenia as risk for fracture. ( 29464358 )
2019
494
Does Trabecular Bone Score (TBS) improve the predictive ability of FRAX® for major osteoporotic fractures according to the Japanese Population-Based Osteoporosis (JPOS) cohort study? ( 29468478 )
2019
495
Prevention of ovariectomy-induced osteoporosis in rats : Comparative study of zoledronic acid, parathyroid hormone (1-34) and strontium ranelate. ( 29476205 )
2019
496
Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer. ( 29520506 )
2019
497
Disease burden of fractures among patients with osteoporosis in Japan: health-related quality of life, work productivity and activity impairment, healthcare resource utilization, and economic costs. ( 29520508 )
2019
498
Changes in quality of life in patients with postmenopausal osteoporosis receiving weekly bisphosphonate treatment: a 2-year multicenter study in Japan. ( 29523963 )
2019
499
The safety and effectiveness profile of eldecalcitol in a prospective, post-marketing observational study in Japanese male patients with osteoporosis. ( 29532248 )
2019
500
Identification of pleiotropic genetic variants affecting osteoporosis risk in a Korean elderly cohort. ( 29273888 )
2019
501
Muscle strength is associated with bone health independently of muscle mass in postmenopausal women: the Japanese population-based osteoporosis study. ( 29282553 )
2019
502
The effect of protein diets in postmenopausal women with osteoporosis: Systematic review of randomized controlled trials. ( 29319467 )
2019
503
Short-term and long-term effects of osteoporosis on incisor teeth and femoral bones evaluated by Raman spectroscopy and energy dispersive X-ray analysis in ovariectomized rats. ( 29344812 )
2019
504
The effect of raloxifene on bone marrow adipose tissue and bone turnover in postmenopausal women with osteoporosis. ( 29032175 )
2019
505
Efficacy of Denosumab for Osteoporosis in Two Patients with Adult-Onset Still's Disease-Denosumab Efficacy in Osteoporotic Still's Disease Patients. ( 29565301 )
2018
506
Untargeted Metabolomics Reveals the Protective Effect of Fufang Zhenshu Tiaozhi (FTZ) on Aging-Induced Osteoporosis in Mice. ( 30670964 )
2018
507
Response to Letter to the Editor: Epigenetic Aging in Osteoporosis. ( 30589450 )
2018
508
Correction: Repeated superovulation increases the risk of osteoporosis and cardiovascular diseases by accelerating ovarian aging in mice. ( 30300138 )
2018
509
Ovarian Aging and Osteoporosis. ( 30232761 )
2018
510
PGC-1α Controls Skeletal Stem Cell Fate and Bone-Fat Balance in Osteoporosis and Skeletal Aging by Inducing TAZ. ( 30244868 )
2018
511
Epigenetic Aging in Osteoporosis. ( 30106493 )
2018
512
Fat and Bone: PGC-1α Regulates Mesenchymal Cell Fate during Aging and Osteoporosis. ( 30075123 )
2018
513
PGC-1α Controls Skeletal Stem Cell Fate and Bone-Fat Balance in Osteoporosis and Skeletal Aging by Inducing TAZ. ( 30017591 )
2018
514
Mito-mice∆ and mitochondrial DNA mutator mice as models of human osteoporosis caused not by aging but by hyperparathyroidism. ( 29973435 )
2018
515
Hidden burden of osteoporosis in alpha-1 antitrypsin deficiency. ( 29950358 )
2018
516
Effects of eldecalcitol and ibandronate on secondary osteoporosis and muscle wasting in rats with adjuvant-induced arthritis. ( 30775555 )
2018
517
Prevalence and Fracture Risk of Osteoporosis in Patients with Rheumatoid Arthritis: A Multicenter Comparative Study of the FRAX and WHO Criteria. ( 30513848 )
2018
518
Osteoporosis Self-Assessment Tool As a Screening Tool for Predicting Osteoporosis in Elderly Chinese Patients With Established Rheumatoid Arthritis. ( 30205984 )
2018
519
Vitamin D and bisphosphonates therapies for osteoporosis are associated with different risks of atrial fibrillation in women: A nationwide population-based analysis. ( 30412111 )
2018
520
Side effects of drugs for osteoporosis and metastatic bone disease. ( 30192026 )
2018
521
Correction: Osteoporosis Self-Assessment Tool for Asians Can Predict Neurologic Prognosis in Patients with Isolated Moderate Traumatic Brain Injury. ( 29889881 )
2018
522
Effectiveness of bisphosphonate combined with activated vitamin D in patients with aromatase inhibitor-induced osteoporosis after breast cancer operation. ( 30775551 )
2018
523
Osteoporosis in primary biliary cholangitis. ( 30131657 )
2018
524
Risk factors for osteoporosis in chronic inflammatory demyelinating polyradiculoneuropathy. ( 29896772 )
2018
525
Risk of osteoporosis in microscopic colitis. ( 29460653 )
2018
526
Osteoporosis as an initial manifestation in a patient with Crohn's disease: A case report. ( 29581748 )
2018
527
Re-evaluating osteoporosis and fracture risk in Crohn's disease patients in the era of TNF-alpha inhibitors. ( 29235392 )
2018
528
Osteoporosis Is Associated with Deteriorating Clinical Status in Adults with Cystic Fibrosis. ( 29780417 )
2018
529
Impact of Osteoporosis on the Risk of Dementia in Almost 60,000 Patients Followed in General Practices in Germany. ( 30056429 )
2018
530
Dental Caries and Osteoporosis. ( 30048347 )
2018
531
Effect of type 2 diabetes mellitus on treatment outcomes of patients with postmenopausal osteoporosis: a retrospective study. ( 30918853 )
2018
532
Osteoporosis and dry eye syndrome: A previously unappreciated association that may alert active prevention of fall. ( 30395639 )
2018
533
Genetic Polymorphisms in the ESR1 and VDR Genes Do Not Correlate With Osteoporosis in Patients With Familial Dysautonomia. ( 28161223 )
2018
534
Prevalence and pathogenesis of osteopenia and osteoporosis in epidermolysis bullosa: An evidence-based review. ( 30118182 )
2018
535
Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis. ( 30323574 )
2018
536
Increased risk of osteoporosis in patients with nonalcoholic fatty liver disease: A population-based retrospective cohort study. ( 30334985 )
2018
537
The Combined Effect of Nonalcoholic Fatty Liver Disease and Metabolic Syndrome on Osteoporosis in Postmenopausal Females in Eastern China. ( 30151008 )
2018
538
Screening for Geriatric Syndromes: Falls, Urinary/Fecal Incontinence, and Osteoporosis. ( 29129217 )
2018
539
Osteoporosis development and vertebral fractures after abdominal irradiation in patients with gastric cancer. ( 30309324 )
2018
540
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis: Comment on the Article by Buckley et al. ( 28941168 )
2018
541
Cost-effectiveness of bisphosphonates for prevention of fracture related to glucocorticoid-induced osteoporosis in Malaysia. ( 29105349 )
2018
542
Significant improvement of bone mineral density by denosumab without bisphosphonate pre-treatment in glucocorticoid-induced osteoporosis. ( 29251033 )
2018
543
Just the FRAX: Management of Glucocorticoid-Induced Osteoporosis. ( 29337149 )
2018
544
Autophagy as a target for glucocorticoid-induced osteoporosis therapy. ( 29427075 )
2018
545
Multiple vertebral fractures associated with glucocorticoid-induced osteoporosis treated with teriparatide followed by kyphosis correction fusion: a case report. ( 29476202 )
2018
546
Intramembranous ossification and endochondral ossification are impaired differently between glucocorticoid-induced osteoporosis and estrogen deficiency-induced osteoporosis. ( 29497100 )
2018
547
The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial. ( 29543887 )
2018
548
Gastrodin alleviates glucocorticoid induced osteoporosis in rats via activating the Nrf2 signaling pathways. ( 29545917 )
2018
549
Effects of the Phosphodiesterase-5 (PDE-5) Inhibitors, Avanafil and Zaprinast, on Bone Remodeling and Oxidative Damage in a Rat Model of Glucocorticoid-Induced Osteoporosis. ( 29557941 )
2018
550
The Efficacy of Minodronate in the Treatment of Glucocorticoid-induced Osteoporosis. ( 29607978 )
2018
551
Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. ( 29631782 )
2018
552
Denosumab: a new treatment option for glucocorticoid-induced osteoporosis. ( 29631783 )
2018
553
Efficacy of Denosumab for Glucocorticoid-Induced Osteoporosis in an Adolescent Patient with Duchenne Muscular Dystrophy: A Case Report. ( 29642113 )
2018
554
Glucocorticoid-induced osteoporosis: an update. ( 29691807 )
2018
555
The osteoblast: Linking glucocorticoid-induced osteoporosis and hyperglycaemia? A post-hoc analysis of a randomised clinical trial. ( 29729427 )
2018
556
Role of Teriparatide in Glucocorticoid-induced Osteoporosis through Regulating Cellular Reactive Oxygen Species. ( 29745033 )
2018
557
Preservation of type H vessels and osteoblasts by enhanced preosteoclast platelet-derived growth factor type BB attenuates glucocorticoid-induced osteoporosis in growing mice. ( 29800693 )
2018
558
Denosumab for glucocorticoid-induced osteoporosis. ( 29849116 )
2018
559
Epigallocatechin-3-Gallate Ameliorates Glucocorticoid-Induced Osteoporosis of Rats in Vivo and in Vitro. ( 29867459 )
2018
560
Effects of quality indicator monitoring for glucocorticoid-induced osteoporosis and trends of drug treatment in a Japanese hospital. ( 29878618 )
2018
561
Myricetin ameliorates glucocorticoid-induced osteoporosis through the ERK signaling pathway. ( 29883721 )
2018
562
Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial. ( 29904824 )
2018
563
GAG and collagen II attenuate glucocorticoid-induced osteoporosis by regulating NF-κB and MAPK signaling. ( 30018717 )
2018
564
Denosumab in the treatment of glucocorticoid-induced osteoporosis. ( 30019224 )
2018
565
Morin protects glucocorticoid-induced osteoporosis through regulating the mitogen-activated protein kinase signaling pathway. ( 30043216 )
2018
566
Ptychographic X-ray CT characterization of the osteocyte lacuno-canalicular network in a male rat's glucocorticoid induced osteoporosis model. ( 30246062 )
2018
567
Combined treatment with cinnamaldehyde and PTH enhances the therapeutic effect on glucocorticoid-induced osteoporosis through inhibiting osteoclastogenesis and promoting osteoblastogenesis. ( 30309646 )
2018
568
Effects of alendronate for treatment of glucocorticoid-induced osteoporosis: A meta-analysis of randomized controlled trials. ( 30334952 )
2018
569
Technetium-99 Conjugated with Methylene Diphosphonate Ameliorates Glucocorticoid Induced Osteoporosis by Inhibiting Osteoclastogenesis. ( 30406140 )
2018
570
Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis. ( 30574464 )
2018
571
Glucocorticoid-Induced Osteoporosis. ( 30586507 )
2018
572
Gout as a risk factor for osteoporosis: epidemiologic evidence from a population-based longitudinal study involving 108,060 individuals. ( 29383389 )
2018
573
Gout as a risk factor for osteoporosis: response to comments by Kostev. ( 29637220 )
2018
574
Association between gout and osteoporosis risk in the United Kingdom. ( 29637221 )
2018
575
Epidemiology of arthritis, chronic back pain, gout, osteoporosis, spondyloarthropathies and rheumatoid arthritis among 1.5 million patients in Australian general practice: NPS MedicineWise MedicineInsight dataset. ( 29347932 )
2018
576
Effects of growth hormone therapy on bone density and fracture risk in age-related osteoporosis in the absence of growth hormone deficiency: a systematic review and meta-analysis. ( 29030774 )
2018
577
Bisphosphonate therapy for spinal osteoporosis in Hajdu-Cheney syndrome - new data and literature review. ( 29618366 )
2018
578
Association Between Possible Osteoporosis and Shunt-Dependent Hydrocephalus After Subarachnoid Hemorrhage. ( 29946014 )
2018
579
Reproductive disorders, osteoporosis and secondary hyperparathyroidism with celiac disease. ( 30701802 )
2018
580
Denosumab-induced Normocalcemic Hyperparathyroidism in a Woman with Postmenopausal Osteoporosis and Normal Renal Function. ( 29879891 )
2018
581
Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism - translating the pharmacology. ( 29049872 )
2018
582
Comparative Effect of rhPTH(1-84) on Bone Mineral Density and Trabecular Bone Score in Hypoparathyroidism and Postmenopausal Osteoporosis. ( 30088838 )
2018
583
Epigenetic enzymes influenced by oxidative stress and hypoxia mimetic in osteoblasts are differentially expressed in patients with osteoporosis and osteoarthritis. ( 30385847 )
2018
584
Impact of prenatal hypoxia on fetal bone growth and osteoporosis in ovariectomized offspring rats. ( 29524565 )
2018
585
Osteoporosis, osteopenia, and inflammatory bowel disease: lessons from a real‑world study. ( 30174323 )
2018
586
Morinda citrifolia L. Leaf Extract Protects against Cerebral Ischemia and Osteoporosis in an In Vivo Experimental Model of Menopause. ( 29765488 )
2018
587
Efficacy and safety of once-monthly risedronate in osteoporosis subjects with mild-to-moderate chronic kidney disease: a post hoc subgroup analysis of a phase III trial in Japan. ( 30523414 )
2018
588
Breathlessness in amyotrophic lateral sclerosis: A case report on the role of osteoporosis in the worsening of respiratory failure. ( 30407295 )
2018
589
Risk factors for osteoporosis in liver cirrhosis patients measured by transient elastography. ( 29768330 )
2018
590
Association between sarcopenia and osteoporosis in chronic liver disease. ( 29734510 )
2018
591
Osteoporosis in chronic liver disease. ( 29479832 )
2018
592
Lung, Fat and Bone: Increased Adiponectin Associates with the Combination of Smoking-Related Lung Disease and Osteoporosis. ( 30374451 )
2018
593
TUBB3 E410K syndrome with osteoporosis and cough syncope in a patient previously diagnosed with atypical Moebius syndrome. ( 29289389 )
2018
594
Bone Health and Osteoporosis Management of the Patient With Duchenne Muscular Dystrophy. ( 30275247 )
2018
595
Proceedings of a Parent Project Muscular Dystrophy Bone Health Workshop: Morbidity due to osteoporosis in DMD: The Path Forward May 12-13, 2016, Bethesda, Maryland, USA. ( 28756052 )
2018
596
Preventing muscle wasting by osteoporosis drug alendronate in vitro and in myopathy models via sirtuin-3 down-regulation. ( 29512306 )
2018
597
Loss of murine Gfi1 causes neutropenia and induces osteoporosis depending on the pathogen load and systemic inflammation. ( 29879182 )
2018
598
Is it possible that the pathogenesis of osteoarthritis could start with subchondral trabecular bone loss like osteoporosis? ( 30376799 )
2018
599
Effects of anti-osteoporosis medications on total hip arthroplasty risks in osteoporotic patients with hip osteoarthritis in Taiwan: a nationwide cohort study. ( 30306268 )
2018
600
World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): Poster Abstracts. ( 30054651 )
2018
601
World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): Committee of National Societies Abstracts. ( 30054652 )
2018
602
World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): Non-Sponsored Symposia Abstracts. ( 30054653 )
2018
603
World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): Meet-the-Expert Abstracts. ( 30054654 )
2018
604
World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): ESPRM-ESCEO-IOF Symposium Abstracts. ( 30054655 )
2018
605
World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): EUGMS-ESCEO-IOF Symposium Abstracts. ( 30054656 )
2018
606
World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): Oral Communication Abstracts. ( 30054657 )
2018
607
World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): ESCEO-WHO Symposia Abstracts. ( 30054658 )
2018
608
World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): Satellite Symposia Abstracts. ( 30054659 )
2018
609
World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): IOF-ESCEO Symposium Abstracts. ( 30054660 )
2018
610
World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): Educational Lecture Abstract. ( 30054661 )
2018
611
World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): Plenary Lectures Abstracts. ( 30054662 )
2018
612
World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): ESCEO Symposia Abstracts. ( 30054663 )
2018
613
World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): Author Index. ( 30054664 )
2018
614
World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases. ( 30054665 )
2018
615
World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases - the "Wco-iof-esceo Congress": The 18th edition of the WCO-IOF-ESCEO Congress - Krakow 2018. ( 30042609 )
2018
616
Ficus deltoidea Prevented Bone Loss in Preclinical Osteoporosis/Osteoarthritis Model by Suppressing Inflammation. ( 29808374 )
2018
617
Benefits and safety of dietary protein for bone health-an expert consensus paper endorsed by the European Society for Clinical and Economical Aspects of Osteopororosis, Osteoarthritis, and Musculoskeletal Diseases and by the International Osteoporosis Foundation. ( 29740667 )
2018
618
Erratum to: World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2016): Poster Abstracts. ( 29404623 )
2018
619
Guidelines for the conduct of pharmacological clinical trials in hand osteoarthritis: Consensus of a Working Group of the European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). ( 29287769 )
2018
620
Bone mineral density in osteoporotic patients with pyogenic vertebral osteomyelitis: effect of early versus late treatment for osteoporosis. ( 30225674 )
2018
621
Conservative surgical treatment of medication related osteonecrosis of the jaw (MRONJ) lesions in patients affected by osteoporosis exposed to oral bisphosphonates: 24 months follow-up. ( 29802059 )
2018
622
Dose-Intensity of Bisphosphonates and the Risk of Osteonecrosis of the Jaw in Osteoporosis Patients. ( 30079024 )
2018
623
Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis. ( 29713913 )
2018
624
Effects of Milk and Dairy Products on the Prevention of Osteoporosis and Osteoporotic Fractures in Europeans and Non-Hispanic Whites from North America: A Systematic Review and Updated Meta-Analysis. ( 31089740 )
2018
625
Osteoporosis, Activities of Daily Living Skills, Quality of Life, and Dietary Adequacy of Congregate Meal Participants. ( 31011062 )
2018
626
The Prevalence and risk factors of osteoporosis among the elderly in Hamadan province: A cross sectional study. ( 30815406 )
2018
627
Application of bone transgenic zebrafish in anti-osteoporosis chemical screening. ( 30891547 )
2018
628
Quercetin rescued TNF-alpha-induced impairments in bone marrow-derived mesenchymal stem cell osteogenesis and improved osteoporosis in rats. ( 30662673 )
2018
629
Sharing Pathological Mechanisms of Insomnia and Osteoporosis, and a New Perspective on Safe Drug Choice. ( 30671405 )
2018
630
Bone Marrow-derived Osteoblasts in the Management of Ovariectomy induced Osteoporosis in Rats. ( 30679890 )
2018
631
ARE TRAUMATOLOGISTS TREATING OSTEOPOROSIS TO PREVENT NEW FRACTURES IN BRAZIL? ( 30774511 )
2018
632
Correction to: Efficacy of radiographic density values of the first and second cervical vertebrae recorded by CBCT technique to identify patients with osteoporosis and osteopenia. ( 30774799 )
2018
633
Factors associated with osteoporosis medication initiation and adherence. ( 30775533 )
2018
634
Romosozumab for the treatment of osteoporosis. ( 30775535 )
2018
635
An updated hip fracture projection in Asia: The Asian Federation of Osteoporosis Societies study. ( 30775536 )
2018
636
Safety and effectiveness of monthly intravenous ibandronate injections in a prospective, postmarketing, and observational study in Japanese patients with osteoporosis. ( 30775537 )
2018
637
Utility of radius bone densitometry for the treatment of osteoporosis with once-weekly teriparatide therapy. ( 30775538 )
2018
638
The importance of updating osteoporotic femur fracture data: Asian Federation of Osteoporosis Societies study. ( 30775540 )
2018
639
Prevalence of osteoporosis and osteopenia in an apparently healthy Indian population - a cross-sectional retrospective study. ( 30775543 )
2018
640
Influence on the bone mineral density and bone metabolism marker after the interruption and reinitiation of monthly minodronate therapy in postmenopausal women with osteoporosis. ( 30775544 )
2018
641
Efficacy, safety, and compliance of ibandronate treatment for 3 years in postmenopausal Japanese women with primary osteoporosis. ( 30775545 )
2018
642
Overcoming osteoporosis and beyond: Locomotive syndrome or dysmobility syndrome. ( 30775547 )
2018
643
A coordination project for improvement of osteoporosis medication use among patients who sustained an osteoporotic fracture: The Israeli experience. ( 30775556 )
2018
644
MicroRNA-543 promotes ovariectomy-induced osteoporosis through inhibition of AKT/p38 MAPK signaling pathway by targeting YAF2. ( 30506950 )
2018
645
Iron chelating properties of Eltrombopag: Investigating its role in thalassemia-induced osteoporosis. ( 30507954 )
2018
646
Treatment of Osteoporosis, with a Focus on 2 Monoclonal Antibodies. ( 30508820 )
2018
647
Cumulative network-meta-analyses, practice guidelines and actual prescriptions of drug treatments for postmenopausal osteoporosis: a study protocol for cumulative network meta-analyses and meta-epidemiological study. ( 30518583 )
2018
648
Screening for osteoporosis: A systematic assessment of the quality and content of clinical practice guidelines, using the AGREE II instrument and the IOM Standards for Trustworthy Guidelines. ( 30521556 )
2018
649
Selected anti-health behaviours among women with osteoporosis ( 30525331 )
2018
650
The gap between women's needs when diagnosed with asymptomatic osteoporosis and what is provided by the healthcare system: A qualitative study. ( 30525980 )
2018
651
Modified SCORE tool for prediction of bone mineral density in Egyptian elderly women. Comparison of seven osteoporosis screening tools. ( 30526422 )
2018
652
Mini-review:Functions and Action Mechanisms of PQQ in Osteoporosis and Neuro Injury. ( 30526470 )
2018
653
One year in review 2018: progress in osteoporosis treatment. ( 30526765 )
2018
654
Effectiveness of thiazides on serum and urinary calcium levels and bone mineral density in patients with osteoporosis: a systematic review and meta-analysis. ( 30532521 )
2018
655
Comparison of denosumab vs. bisphosphonates in osteoporosis patients: A meta-analysis of randomized controlled trials. ( 30535289 )
2018
656
Development of an in house ELISA for human intact osteocalcin and its utility in diagnosis and management of osteoporosis. ( 30537473 )
2018
657
Correction to: Age-related normative values of trabecular bone score (TBS) for Japanese women: the Japanese Population-based Osteoporosis (JPOS) study. ( 30539270 )
2018
658
Screening, prevention and management of osteoporosis among Canadian adults. ( 30540411 )
2018
659
Frequency of Osteoporosis and Vertebral Fractures in Chronic Obstructive Pulmonary Disease (COPD) Patients. ( 30541669 )
2018
660
Osteoporosis: a clinical and pharmacological update. ( 30542797 )
2018
661
Celiac Disease Diagnosed through Screening Programs in At-Risk Adults Is Not Associated with Worse Adherence to the Gluten-Free Diet and Might Protect from Osteopenia/Osteoporosis. ( 30544494 )
2018
662
Association of vitamin D receptor ApaI gene polymorphism with osteoporosis susceptibility in postmenopausal Han Chinese women in Xinjiang. ( 30546875 )
2018
663
Benign paroxysmal positional vertigo and osteoporosis. ( 30554357 )
2018
664
V-ATPases and osteoclasts: ambiguous future of V-ATPases inhibitors in osteoporosis. ( 30555553 )
2018
665
The correlation between estrogen receptor gene polymorphism and osteoporosis in Han Chinese women. ( 30556843 )
2018
666
Mitochondrial protein OPA mediates osteoporosis induced by radiation through the P38 signaling pathway. ( 30556844 )
2018
667
The facile synthesis of copper oxide quantum dots on chitosan with assistance of phyto-angelica for enhancing the human osteoblast activity to the application of osteoporosis. ( 30557790 )
2018
668
The effects of concurrent training (aerobic-resistance) and milk consumption on some markers of bone mineral density in women with osteoporosis. ( 30558600 )
2018
669
Influence of bone densitometry on the anti-osteoporosis treatment after fragility hip fracture. ( 30560430 )
2018
670
Oral bisphosphonates and incidence of cancers in patients with osteoporosis: a systematic review and meta-analysis. ( 30560459 )
2018
671
Chronic Urticaria and Osteoporosis: A longitudinal, Community-based Cohort Study of 11,944 Patients. ( 30560994 )
2018
672
Elevated serum CCL4/MIP-1β levels in postmenopausal osteoporosis patients are linked with disease severity. ( 30561228 )
2018
673
Positive Association between Dietary Inflammatory Index and the Risk of Osteoporosis: Results from the KoGES_Health Examinee (HEXA) Cohort Study. ( 30563032 )
2018
674
Detection of Osteoporosis from Percussion Responses Using an Electronic Stethoscope and Machine Learning. ( 30563076 )
2018
675
Osteoporosis risk of the subjects with isolated lactase enzyme deficiency. ( 30564862 )
2018
676
Special form of osteoporosis in a 53-year-old man. ( 30567240 )
2018
677
The Contribution of Alcohol Dehydrogenase 3 to the Development of Alcoholic Osteoporosis in Mice. ( 30568058 )
2018
678
Identification of gene biomarkers in patients with postmenopausal osteoporosis. ( 30569177 )
2018
679
Osteoporosis in Older Persons: Old and New Players. ( 30570741 )
2018
680
Vitamin D Receptor in Muscle Atrophy of Elderly Patients: A Key Element of Osteoporosis-Sarcopenia Connection. ( 30574409 )
2018
681
Osteoporosis and Osteoporotic Fractures in Gastrointestinal Disease. ( 30574465 )
2018
682
Bergapten suppresses RANKL-induced osteoclastogenesis and ovariectomy-induced osteoporosis via suppression of NF-κB and JNK signaling pathways. ( 30579598 )
2018
683
Secular trends in incidence of osteoporosis in Taiwan: A nationwide population-based study. ( 30580795 )
2018
684
Hip fracture rates and time trends in use of anti-osteoporosis medications in Denmark for the period 2005 to 2015: Missed opportunities in fracture prevention. ( 30583122 )
2018
685
Proanthocyanidins inhibit osteoclast formation and function by inhibiting the NF-κB and JNK signaling pathways during osteoporosis treatment. ( 30583865 )
2018
686
Health-related quality of life in Romanian postmenopausal women with osteoporosis and fragility fractures. ( 30584286 )
2018
687
Age at First Osteoporosis Screening Among Older Women and Men: Is Bone Mineral Density Measurement Ordered Timely? ( 30585552 )
2018
688
Anabolic Therapies in Osteoporosis and Bone Regeneration. ( 30587780 )
2018
689
Clinical effects of the bridge-type ROI-C interbody fusion cage system in the treatment of cervical spondylosis with osteoporosis. ( 30587947 )
2018
690
Osteoporosis Changes Collagen/Apatite Orientation and Young's Modulus in Vertebral Cortical Bone of Rat. ( 30588540 )
2018
691
Milk drinking and risk of hip fracture. The Norwegian Epidemiologic Osteoporosis Studies (NOREPOS). ( 30588895 )
2018
692
Melatonin: Another avenue for treating osteoporosis? ( 30597617 )
2018
693
Positive Effects of Bisphosphonates on Osteogenic Differentiation in Patient-Derived Mesenchymal Stem Cells for the Treatment of Osteoporosis. ( 30603570 )
2018
694
Efficacy, cost, and aspects to take into account in the treatment of osteoporosis in the elderly. ( 30606499 )
2018
695
The mechanical loading and muscle activation of four common exercises used in osteoporosis prevention for early postmenopausal women. ( 30611015 )
2018
696
Osteoporosis Knowledge Among Spine Surgery Patients. ( 30619672 )
2018
697
Sex effects on the association between sarcopenia EWGSOP and osteoporosis in outpatient older adults: data from the SARCOS study. ( 30624502 )
2018
698
Gossypol Promotes Bone Formation in Ovariectomy-Induced Osteoporosis through Regulating Cell Apoptosis. ( 30643801 )
2018
699
Transient osteoporosis of pregnancy in a case of postpartum bilateral femoral neck fracture. ( 30643860 )
2018
700
Osteoporosis Treatment After Hip Fracture: Bad News and Getting Worse. ( 30646027 )
2018
701
Association of Osteoporosis Medication Use After Hip Fracture With Prevention of Subsequent Nonvertebral Fractures: An Instrumental Variable Analysis. ( 30646034 )
2018
702
Improvement in the primary and secondary prevention of osteoporosis by a Fracture Liaison Service: feedback from a single French center care pathway. ( 30324242 )
2018
703
CircRUNX2 through has-miR-203 regulates RUNX2 to prevent osteoporosis. ( 30324718 )
2018
704
Mechanisms of Zuogui Pill in Treating Osteoporosis: Perspective from Bone Marrow Mesenchymal Stem Cells. ( 30327678 )
2018
705
Association between polycyclic aromatic hydrocarbons and osteoporosis: data from NHANES, 2005-2014. ( 30334129 )
2018
706
Is the exposure to bisphosphonates or osteoporosis the predictor of spinal radiographic progression in ankylosing spondylitis? ( 30336776 )
2018
707
Bone marrow stem cells-derived exosomes extracted from osteoporosis patients inhibit osteogenesis via microRNA-21/SMAD7. ( 30338786 )
2018
708
Systemic bone loss, impaired osteogenic activity and type I muscle fiber atrophy in mice with elastase-induced pulmonary emphysema: Establishment of a COPD-related osteoporosis mouse model. ( 30342225 )
2018
709
MicroRNA-874 targeting SUFU involves in osteoblast proliferation and differentiation in osteoporosis rats through the Hedgehog signaling pathway. ( 30342851 )
2018
710
Transfer RNA-derived fragments as potential exosome tRNA-derived fragment biomarkers for osteoporosis. ( 30345646 )
2018
711
High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis. ( 30349211 )
2018
712
Comparative anti-fracture effectiveness of different oral anti-osteoporosis therapies based on "real-world" data: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database. ( 30349390 )
2018
713
Green tea (Camellia sinensis) aqueous extract alleviates postmenopausal osteoporosis in ovariectomized rats and prevents RANKL-induced osteoclastogenesis in vitro. ( 30349445 )
2018
714
Long Non-coding RNAs: A New Regulatory Code for Osteoporosis. ( 30349507 )
2018
715
Self-efficacy of osteoporosis preventive behaviors and its predictors in Iranian adolescents. ( 30352030 )
2018
716
Updates in CKD-Associated Osteoporosis. ( 30353319 )
2018
717
Paper-based microfluidic device for diagnosis of osteoporosis markers. ( 30354201 )
2018
718
Lycopene influences osteoblast functional activity and prevents femur bone loss in female rats submitted to an experimental model of osteoporosis. ( 30357566 )
2018
719
Screening for Osteoporosis to Prevent Fractures: Recommendation Statement. ( 30365294 )
2018
720
Screening for Osteoporosis to Prevent Fractures. ( 30365296 )
2018
721
The Bromodomain Inhibitor N-Methyl pyrrolidone Prevents Osteoporosis and BMP-Triggered Sclerostin Expression in Osteocytes. ( 30366476 )
2018
722
Treatment recommendations based on fracture risk status are not consistently provided in osteoporosis guidelines. ( 30367203 )
2018
723
Usefulness of measuring radiographic density of axis vertebra in patients at risk of osteoporosis: A cone-beam computed tomography study. ( 30369793 )
2018
724
Association Between Osteoporosis and Age-Related Macular Degeneration: The Korea National Health and Nutrition Examination Survey. ( 30372730 )
2018
725
Medication Decision-making in Osteoporosis: Can We Explain Why Patients Do Not Take Their Osteoporosis Medications? ( 30374627 )
2018
726
Osteoporosis Management Following Teriparatide Therapy For Vertebral Fractures: Are Patients On Correct Maintenance Therapy? ( 30376242 )
2018
727
Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial. ( 30381400 )
2018
728
New and emerging concepts in the use of denosumab for the treatment of osteoporosis. ( 30386439 )
2018
729
Novel therapies in osteoporosis: PTH-related peptide analogues and inhibitors of sclerostin. ( 30389901 )
2018
730
GOLM1 Stimulation of Glutamine Metabolism Promotes Osteoporosis via Inhibiting Osteogenic Differentiation of BMSCs. ( 30396165 )
2018
731
Correction to: Is the exposure to bisphosphonates or osteoporosis the predictor of spinal radiographic progression in ankylosing spondylitis? ( 30396370 )
2018
732
Help at hand: Women's experiences of using a mobile health application upon diagnosis of asymptomatic osteoporosis. ( 30397471 )
2018
733
High prevalence and correlates of osteoporosis in men aged 50  years and over: A nationwide osteoporosis survey in Taiwan. ( 30397998 )
2018
734
The Effectiveness of a Private Orthopaedic Practice-Based Osteoporosis Management Service to Reduce the Risk of Subsequent Fractures. ( 30399076 )
2018
735
Open-label study of treatment with alendronate sodium plus vitamin D in men and women with osteoporosis in Thailand. ( 30400864 )
2018
736
Integrative Bone Metabolomics-Lipidomics Strategy for Pathological Mechanism of Postmenopausal Osteoporosis Mouse Model. ( 30405156 )
2018
737
Osteoporosis Conference 2018 Birmingham, UK 2 - 4 December 2018 Abstracts. ( 30406308 )
2018
738
Osteoporosis in postmenopausal women in this decade: a bibliometric assessment of current research and future hotspots. ( 30406425 )
2018
739
Bone and muscle specific circulating microRNAs in postmenopausal women based on osteoporosis and sarcopenia status. ( 30408612 )
2018
740
Decreased microRNA-182-5p helps alendronate promote osteoblast proliferation and differentiation in osteoporosis via the Rap1/MAPK pathway. ( 30413613 )
2018
741
A systematic review of factors affecting medication adherence among patients with osteoporosis. ( 30417253 )
2018
742
We miss the opportunity: Pretreament of osteoporosis in a German trauma center. ( 30418992 )
2018
743
Changes in bone mineral density (BMD): a longitudinal study of osteoporosis patients in the real-world setting. ( 30421141 )
2018
744
Hormonal Risk Factors for Osteoporosis: Different Profile Among Antipsychotics. ( 30421978 )
2018
745
Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study. ( 30424783 )
2018
746
Endocrine Conditions in Older Adults: Osteoporosis. ( 30427648 )
2018
747
Mettl3-mediated m6A RNA methylation regulates the fate of bone marrow mesenchymal stem cells and osteoporosis. ( 30429466 )
2018
748
Effect of osteoporosis on the clinical and radiological outcomes following one-level posterior lumbar interbody fusion. ( 30431006 )
2018
749
Using Octuplet Siamese Network For Osteoporosis Analysis On Dental Panoramic Radiographs. ( 30440935 )
2018
750
Influence of DNA methylation on the expression of OPG/RANKL in primary osteoporosis. ( 30443169 )
2018
751
Prevalence of osteoporosis with the World Health Organization diagnostic criteria in the Eastern Mediterranean Region: a systematic review and meta-analysis. ( 30448960 )
2018
752
Postmenopausal osteoporosis: Assessment and management. ( 30449552 )
2018
753
Update on osteoporosis in men. ( 30449553 )
2018
754
FRAX® based intervention thresholds for management of osteoporosis in Singaporean women. ( 30456726 )
2018
755
Efficacy and safety of alfacalcidol in Chinese postmenopausal women aged over 65 with osteoporosis or osteopenia: An open label, non-comparative, post marketing observational study. ( 30461612 )
2018
756
Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis. ( 30461654 )
2018
757
A comprehensive overview on osteoporosis and its risk factors. ( 30464484 )
2018
758
Erratum: Experience with alendronate treatment for four years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures [Expression of concern]. ( 30464486 )
2018
759
Comparison of Osteoporosis Pharmacotherapy Fracture Rates: Analysis of a MarketScan® Claims Database Cohort. ( 30464768 )
2018
760
High-throughput metabolomics investigates anti-osteoporosis activity of oleanolic acid via regulating metabolic networks using ultra-performance liquid chromatography coupled with mass spectrometry. ( 30466629 )
2018
761
MOTS-c improves osteoporosis by promoting osteogenic differentiation of bone marrow mesenchymal stem cells via TGF-β/Smad pathway. ( 30468456 )
2018
762
Recommendations by the Spanish Society of Rheumatology on Osteoporosis. ( 30470636 )
2018
763
Vertebral spine osteoporosis treatment efficacy in local population: A clinical study. ( 30473503 )
2018
764
Efficacy and Safety of Denosumab Therapy for Osteogenesis Imperfecta Patients with Osteoporosis-Case Series. ( 30477250 )
2018
765
Highly Potent 17β-HSD2 Inhibitors with a Promising Pharmacokinetic Profile for Targeted Osteoporosis Therapy. ( 30480443 )
2018
766
The effect of zoledronic acid on middle ear osteoporosis: An animal study. ( 30481855 )
2018
767
Subjective benign paroxysmal positional vertigo in patients with osteoporosis or migraine. ( 30482521 )
2018
768
Osteoporosis complicating some inborn or acquired diseases. ( 30484671 )
2018
769
Advances in osteoporosis from 1970 to 2018. ( 30489459 )
2018
770
Limited Osteoporosis Screening Effectiveness Due to Low Treatment Rates in a National Sample of Older Men. ( 30497697 )
2018
771
Evaluating the possible association between systemic osteoporosis and periodontal disease progression in postmenopausal women. ( 30502098 )
2018
772
Effects of the Hydroalcoholic Extract of the Psidium guajava Fruit on Osteoporosis Prevention in Ovariectomized Rats. ( 30510339 )
2018
773
Osteoporosis increases the risk of benign paroxysmal positional vertigo: a nested case-control study using a national sample cohort. ( 30511104 )
2018
774
Biological Activities of Lactose-Based Prebiotics and Symbiosis with Probiotics on Controlling Osteoporosis, Blood-Lipid and Glucose Levels. ( 30513975 )
2018
775
Clinical Use of Opportunistic Computed Tomography Screening for Osteoporosis. ( 30516631 )
2018
776
The High Prevalence of Osteoporosis as a Preventable Disease: The Need for Greater Attention to Prevention Programs in Iran. ( 30186800 )
2018
777
18F-FDG PET/CT in a Patient With Pregnancy and Lactation-Associated Osteoporosis. ( 30188874 )
2018
778
Real-world Management of Women with Postmenopausal Osteoporosis Treated with Denosumab: A Prospective Observational Study in the Czech Republic and Slovakia. ( 30191465 )
2018
779
Global sagittal alignment in elderly patients with osteoporosis and its relationship with severity of vertebral fracture and quality of life. ( 30194552 )
2018
780
Decreased intramuscular calcium hydroxyapatite implant resorption in a murine model of osteoporosis. ( 30194683 )
2018
781
Effects of RANKL Knockdown by Virus-like Particle-Mediated RNAi in a Rat Model of Osteoporosis. ( 30195781 )
2018
782
The efficacy and safety of herbal medicine BHH10 in postmenopausal women with osteoporosis: study protocol for a phase II, multicenter, randomized, double-blinded, placebo-controlled clinical trial. ( 30201024 )
2018
783
Osteoporosis of the vertebra and osteochondral remodeling of the endplate causes intervertebral disc degeneration in ovariectomized mice. ( 30201052 )
2018
784
Incidence of Osteoporosis-Related Complications Following Posterior Lumbar Fusion. ( 30202709 )
2018
785
Dietary Natural N-Acetyl-d-Glucosamine Prevents Bone Loss in Ovariectomized Rat Model of Postmenopausal Osteoporosis. ( 30205615 )
2018
786
Shared variants for osteoporosis and T2DM. ( 30206383 )
2018
787
Osteoporosis effect on posterior mandible in preimplanted area for postmenopausal females using cone-beam computed tomography. ( 30210186 )
2018
788
Use of Bioelectrical Impedance Analysis for the Measurement of Appendicular Skeletal Muscle Mass/Whole Fat Mass and Its Relevance in Assessing Osteoporosis among Patients with Low Back Pain: A Comparative Analysis Using Dual X-ray Absorptiometry. ( 30213166 )
2018
789
Minimally Invasive Augmented Fixation for Anatomical Reduction of Grade 2 and Grade 3 Listhesis in Patients with Osteoporosis. ( 30213172 )
2018
790
Autophagy in osteoporosis: Relation to oxidative stress. ( 30216504 )
2018
791
Sanggenon C Stimulates Osteoblastic Proliferation and Differentiation, Inhibits Osteoclastic Resorption, and Ameliorates Prednisone-Induced Osteoporosis in Zebrafish Model. ( 30217005 )
2018
792
Activation of JNK signaling in osteoblasts is inversely correlated with collagen synthesis in age-related osteoporosis. ( 30217450 )
2018
793
Celastrol inhibits glucocorticoid‑induced osteoporosis in rat via the PI3K/AKT and Wnt signaling pathways. ( 30221712 )
2018
794
Epigallocatechin‑3‑gallate protects against secondary osteoporosis in a mouse model via the Wnt/β‑catenin signaling pathway. ( 30221714 )
2018
795
Possible therapeutic potential of berberine in the treatment of STZ plus HFD-induced diabetic osteoporosis. ( 30223099 )
2018
796
Chaperonin 60 sustains osteoblast autophagy and counteracts glucocorticoid aggravation of osteoporosis by chaperoning RPTOR. ( 30224697 )
2018
797
Osteoporosis and Jaw Abnormalities in Panoramic Radiography of Chronic Liver Failure Patients. ( 30225253 )
2018
798
Not Salt But Sugar As Aetiological In Osteoporosis: A Review. ( 30228731 )
2018
799
Functional Calcium Binding Peptides from Pacific Cod (Gadus macrocephalus) Bone: Calcium Bioavailability Enhancing Activity and Anti-Osteoporosis Effects in the Ovariectomy-Induced Osteoporosis Rat Model. (